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Parkinson's disease causes a characteristic combination of motor symptoms due to progressive neurodegeneration
of dopaminergic neurons in the substantia nigra pars compacta. The core impairment of dopaminergic neuro-
transmission has motivated the use of functional magnetic resonance imaging (fMRI) in patients with Parkinson's
disease to elucidate the role of dopamine in motor control and cognition in humans. Here we review the main
insights from functional brain imaging in Parkinson's disease. Task-related fMRI revealed many disease-related
alterations in brain activation patterns. However, the interpretation of these ﬁndings is complicated by the fact
that task-dependent activity is inﬂuenced by complex interactions between the amount of dopaminergic neuro-
degeneration in the task-relevant nuclei, the state of medication, genetic factors and performance. Despite these
ambiguities, fMRI studies in Parkinson's disease demonstrated a central role of dopamine in the generation of
movement vigour (bradykinesia) and the control of excessive movements (dyskinesia), involving changes of both
activity and connectivity of the putamen, premotor and motor regions, and right inferior frontal gyrus (rIFG). The
fMRI studies addressing cognitive ﬂexibility provided convergent evidence for a non-linear, U-shaped, relation-
ship between dopamine levels and performance. The amount of neurodegeneration in the task-relevant dopa-
minergic nuclei and pharmacological dopamine replacement can therefore move performance either away or
towards the task-speciﬁc optimum. Dopamine levels also strongly affect processing of reward and punishment for
optimal learning. However, further studies are needed for a detailed understanding of the mechanisms underlying
these effects.1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disor-
der, which causes a characteristic combination of motor symptoms,
comprising slowness of movement (bradykinesia), increased muscle
tone (rigidity), shaking (tremor), and impaired postural control. The
neuropathological hallmark of PD is the presence of alpha-synuclein
inclusions called Lewy-bodies in neurons, associated with progres-
sive loss of dopaminergic neurons in the substantia nigra pars com-
pacta (Kalia and Lang, 2015). Despite early, prevalent and disabling
non-motor features, PD has for many years mainly been viewed as afor Magnetic Resonance (DRCM
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vier Inc. This is an open access armovement disorder. Accordingly, pathophysiological models of PD
have mainly focussed on neurodegeneration of dopaminergic neurons
in the ventral tier of the substantia nigra (SN) and its projections to the
dorsal (‘motor’) striatum (Fearnley and Lees, 1991; Jellinger, 1999).
Dopamine replacement therapy effectively alleviates many of the
motor symptoms of PD, especially during the ﬁrst years after clinical
disease onset. This qualiﬁes PD as a valuable disease model for un-
derstanding the motor dopaminergic system in the healthy brain by
mapping changes in neural activity between unmedicated patients in a
dopamine-depleted state and medicated patients with restored dopa-
mine levels and healthy controls. Yet, an exclusive focus on the motorR), Centre for Functional and Diagnostic Imaging and Research, Copenhagen
vember 2018
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several important aspects of PD. First, the dopaminergic system is not
uniformly affected by neurodegeneration, dopaminergic neurons in
the ventral tegmental area (VTA) are less affected by neuro-
degeneration (Alberico et al., 2015). In addition, neurodegeneration
also affects other neuromodulatory systems including noradrenergic
(NA), cholinergic and serotonergic neurotransmitter system (Braak
et al., 2003; Hawkes et al., 2010) with which dopamine can interact.
This multi-system involvement explains why PD patients frequently
suffer from several disabling ‘non-motor’ symptoms that oftentimes
are changed in intensity, but not effectively treated, by dopaminergic
medication (Schapira et al., 2017).
PD was among the ﬁrst clinical applications of functional neuro-
imaging, from the 1980's onwards (Rowe and Siebner, 2012).
Well-designed imaging studies in PD provided valuable insights, not only
into the disease, but also into the functioning of dopaminergic systems
relevant to the healthy brain.
One way to capture dopamine-related changes in brain function, is to
test patients in two dopamine states; once after dopamine withdrawal
with relatively low levels of dopamine in a pragmatic OFF-medication
state and once after dopamine intake with relatively high levels of
dopamine in an ON-medication state. The differences in the patient's
behaviour and neural activation between the ON- and OFF-medication
state, considered together with the behaviour and activation patterns
of healthy control participants, is then used to infer the functional effects
of dopamine in the human brain.
Another useful approach is to include PD patients who developed
an unwanted effect of dopamine replacement, such as involuntary
‘dyskinesia’ movements or impulse control disorders (ICD), reﬂecting
deleterious side effects of dopamine replacement therapy. Comparing
how dopamine alters behaviour and neural activation in patients who
develop side effects versus patients who do not, provides a better
understanding of dopamine-mediated mechanisms of behaviour. For
instance, dopamine induced dyskinesia can be conceptualized as
aberrant modulation of movement vigour while the emergence of
ICDs can be seen as dysfunctional computation of reward prediction
errors. Thus, these studies are not only informative on mechanisms
mediating side effects of dopamine in PD, but also elucidate the role
of dopamine in cognition and behaviour. For an overview over the
literature applying different combinations of these approaches, see
Table 1.
Another neuroimaging strategy is to relate inter-individual differ-
ences in behaviour and neural activity to inter-individual differences in
dopamine deﬁciency. The latter can for example be assessed by single-
photon emission computed tomography (SPECT) or positron emission
tomography (PET) imaging markers of neurodegeneration (e.g. Aarts
et al., 2012) or quantiﬁcation of dopamine-related motor symptoms (e.g.
Rowe et al., 2008). Rather than comparing patients with healthy con-
trols, this approach exploits the strong heterogeneity of dopamine deﬁ-
ciency in patients with PD.
Other neuroimaging modalities have also contributed substantially
to our understanding and diagnosis of PD, for example structural MRI
using diffusion MRI, MRI sequences sensitive to local iron or neuro-
melanin concentrations, or volume based morphometry (Lehericy
et al., 2017). Other neuroimaging studies have explored the impact of
genetic factors in PD (Robbins et al., 2016). For example, poly-
morphism of the catechol-o-methyltransferase (COMT) gene that
metabolises dopamine in the frontal cortex leads to differences in the
activity of executive cognition systems in PD and in health and can
explain some of the heterogeneity of effects among patients (Nombela
et al., 2014b).
Finally, there exists a large body of literature on resting-state neuro-
imaging having established consistent changes in PD related to motor
and cognitive dysfunction (e.g. Eidelberg, 2009; Kim et al., 2017; Spet-
sieris et al., 2015; Tahmasian et al., 2015; Tang et al., 2010; Vo et al.,
2017; Zhuang et al., 2018). However, given the absence of a direct80relation to behaviour in these studies, we will only refer to this literature
where it is relevant with respect to the functional neuroimaging studies
discussed.
It should also be noted that dopaminergic challenges in healthy
subjects can further elucidate the role of this neurotransmitter in the
healthy brain (e.g. Beierholm et al., 2013; Fiore et al., 2018; Rigoli et al.,
2016). Yet, the focus of this review is on the contribution of PD research
to our understanding of the diseased and the healthy brain and studies on
healthy participants will not be discussed.
In the following sections, we illustrate the value of functional brain
imaging studies of motor and non-motor functions in PD. We focus on
functional neuroimaging studies that have contributed to our under-
standing of physiological and pathological functions of dopamine and
only include important structural and genetic imaging studies where they
complement the functional data. Furthermore, the non-motor symptoms
of PD span many domains, such as sleep, mood, autonomic function,
sensory processing or pain. Here, we focus on cognitive symptoms that
are typically modulated by dopamine. The selected studies are summa-
rized in Table 1.
2. Motor control in Parkinson's disease
2.1. Slowness of movement
Bradykinesia is a clinical hallmark of PD and comprises the slowing
of movement initiation as well as a progressive reduction in speed and
amplitude during repetitive actions (Hughes et al., 1992). Bradyki-
nesia has been attributed to an impaired ability to optimally modulate
movement vigour, resulting in a failure to sufﬁciently “charge”
movement speed, amplitude and frequency during motor execution
(Hallett and Khoshbin, 1980). A lack of vigour is also relevant to
akinesia which is another prominent motor symptom of PD and refers
to poverty or absence of movements (Hallett and Khoshbin, 1980;
Massano and Bhatia, 2012; Turner et al., 2003). Some authors differ-
entiate hypokinesia from bradykinesia with the former describing a
decrease in amplitude (e.g. micrographia) and the latter a reduction in
the speed of movements (Berardelli et al., 2001). However, in most
studies the terms hypo- and bradykinesia are used interchangeably. A
prominent theory interprets bradykinesia and akinesia as an impaired
ability to assign appropriate kinematics to selected actions, putatively
due to an abnormal computation of vigour costs (Baraduc et al., 2013;
Bouc et al., 2016; Mazzoni et al., 2007; Niv et al., 2007; Panigrahi
et al., 2015).
Bradykinesia is the core parkinsonian symptom that most closely
correlates with dopamine deﬁciency (Bernheimer et al., 1973; Vinger-
hoets et al., 1997). Furthermore, bradykinesia responds well to dopamine
replacement therapy (Birkmayer and Hornykiewicz, 1961; Cotzias et al.,
1969; Hauser, 2009), corroborating the notion that dopamine plays an
important role in modulating movement vigour. Precise modulation of
movement vigour is central to skilful movements (Dudman and Krakauer,
2016). Hence, a better understanding of how changes in dopamine
neurotransmission impact on motor circuits controlling movement ki-
nematics is not only relevant for PD research, but for motor neuroscience
in general.
Herz et al. (2014b) aimed to quantify the results of previously
conducted fMRI and H2O-PET studies in PD using an activation like-
lihood estimation meta-analysis approach (Fig. 1). Consistent differ-
ences were primarily found in caudal (“motor”) putamen where
patients with PD showed less movement-related activation than
healthy controls and where dopamine replacement increased
task-related motor activation. Furthermore, studies that included more
severely affected PD patients, with presumably lower levels of striatal
dopamine, were more likely to show a decrease in putaminal activa-
tion during motor tasks. At the cortical level, neuroimaging results
were less consistent. Motor activation of inferior parietal cortex, su-
perior parietal lobule, primary motor cortex (M1) and
Table 1
Selected publications studying patients with PD during motor paradigms, paradigms related to cognitive and behavioural control, paradigms related to reward and
punishment, resting state and on structural changes.
Authors Year Participants (disease severity) Medication state Paradigm Main ﬁndings in patients with Parkinson's disease
Activation during motor tasks
Buhmann
et al.
2003 8 (drug-naïve, H&Y 1–1.5) OFF/ON Simple paced ﬁnger
opposition task
Decreased activity in SMA and M1 in the OFF state. L-Dopa
increases activity in SMA and M1
Cerasa et al. 2012 10 LID (UPDRS total 18), 10 non-
LID (UPDRS total 15)
OFF Simple internally and
externally paced ﬁnger
tapping
LID patients with higher activity in preSMA and rIFG
compared to non-LID patients. preSMA activity correlated
positively, rIFG negatively with LID severity.
Cerasa,
Donzuso
et al.
2015 12 LID (29.8), 12 non-LID (25.7) OFF/OFF to ON Stop-signal task Levodopa-induced increase in SMA activity during errors of
commission and decreased rIFG activity during successful
inhibition compared to non-LID patients.
Herz et al. 2014 13 LID (32.5), 13 non-LID (32.9) OFF/OFF to ON GoNogo task During NoGo trials, levodopa led to stronger activity
increase in preSMA and putamen in LID patients, preSMA
increase correlated with LID severity.
Herz et al. 2015 13 LID (32.5), 13 non-LID (32.9) OFF/OFF to ON GoNogo task Levodopa-induced change in putamen to M1 connectivity in
LID patients only. Levodopa-induced putamen to M1 and to
preSMA connectivity change correlated with LID severity.
Kraft et al. 2009 12 (21.0) OFF/ON Simple uni- and bimanual
power grip
Decreased activity in putamen in OFF state compared to
healthy controls, no difference in ON state.
Spraker et al. 2010 14 (drug-naïve, UPDRS total
17.93)
OFF Two simple grip-slip force
tasks
Slow-paced task: decreased activity in putamen, GPe and
thalamus. High-paced task: decreased activity in all BG
nuclei, thalamus, M1 and SMA.
Turner et al. 2003 12 (41.4) OFF PET study
Simple visuomanual joystick
tracking task
Increase in velocity leads to increased putaminal activity
only in patients.
Activation studies of cognitive and behavioural control
Aarts et al. 2014 15 (ON 20.5, OFF 29.3) OFF/ON Task-switching with different
reward levels
ON state reduced VS response to reward anticipation,
stronger attenuation improved task performance more.
Stronger DS increase ON improved task-switching.
Cools et al. 2007 14 (15.9) OFF/ON Probabilistic reversal learning
task
VS response to errors preceding behavioural switch was
reduced ON compared to OFF
Hughes et al. 2010 16 (18.9 ON, 31.3 OFF), 43
healthy controls
OFF/ON Free choice vs. speciﬁed
button presses
Patients showed more perseveration than controls, this was
exacerbated ON, suggesting overdosing. Higher disease
severity associated with decreased vlPFC and PM activity.
Hughes et al. 2013 17 (10.5 ON, 22.2 OFF), 18
healthy controls
OFF/ON Free choice vs. speciﬁed
button presses
Higher disease severity led to less perseveration ON
compared to OFF and to higher caudate activity when
repeating an action.
MacDonald
et al.
2011 22 (ON 17.22, OFF 22.36), 22
healthy controls
OFF/ON Simple selection task with
congruent and incongruent
stimuli
Patients OFF show less interference by incongruent cues, ON
brings interference to level seen in controls. In controls,
congruent stimuli elicit VS activity, incongruent DS.
Rae et al. 2016 19 (ON 25.87), 20 controls ON DRT, OFF/
ON atom.
GoNogo/stop-signal OFF atom. longer SSRT, reduced stopping activity in rIFG,
preSMA, putamen and STN. ON atom. restored rIFG-preSMA
connectivity.
Rowe et al. 2008 19 (19.2 ON, 31.9 OFF), 19
controls
OFF/ON Bimodality continuous
performance task
Left vlPFC and mid-caudate activation with nonlinear U-
shaped relationship to motor disease severity. L-Dopa shifted
this U-shaped function, indicating differential
neurodegeneration in distinct connections between cortex
and BG.
Ye et al. 2015 21 (20.6 ON), 20 controls ON DRT, OFF/
ON atom.
GoNogo/stop-signal OFF atom. longer SSRT, reduced stopping activity in rIFG
and rIFG-striatum connectivity compared to controls.
Activation studies of reward, punishment and learning
O'Sullivan
et al.
2011 11 ICD (24.1 ON, 43.3 OFF) 7 non-
ICD (22.0 ON, 37.4 OFF)
OFF/ON PET study
Passive viewing of reward-
cues
Decreased D2/D3 binding (increased dopamine release) in
VS to reward-related cues compared to neutral cues in ICD
compared to non-ICD ON medication.
Politis et al. 2013 12 hypersexuality-ICD (23.1 ON,
40.2 OFF), 12 non-ICD (20.0 ON,
34.9 OFF)
OFF/ON Passive viewing of reward-
cues (including sexually
themed) and neutral cues
No interaction between medication and ICD status, but
increased activity in several brain regions, including VS, to
sexual cues independent of medication.
Ray et al. 2012 7 ICD (21.00), 7 non-ICD (17.14) ON PET study
Gambling task and control
task
Decreased D2/D3 binding (increased dopamine release) in
midbrain (approx. SN and VTA) in non-ICD patients in
gambling task compared to control task. No such reduction
in ICD patients.
Schmidt et al. 2014 21 (12.7 ON, 17.3 OFF, 17.3
OFF þ placebo)
OFF/ON/
OFF þ placebo
Reinforcement learning task ON and placebo reduced reward prediction error signal in VS
and increased vmPFC activity for value of rewarding
options.
Shiner et al. 2012 13 (H&Y 1.69) OFF/ON/
OFF þ ON
Reinforcement learning task In a 2-stage learning task, medication did not affect learning
stage, but ON improved performance phase. In performance
phase, vmPFC and VS increased activity with option value
ON only.
Steeves et al. 2009 7 ICD (25.2), 7 non-ICD(20.2) OFF PET study
Gambling task
Reduced D2/D3 binding (increased dopamine release) in VS
in ICD patients during gambling compared to non-ICD.
van der Vegt
et al.
2013 13 (drug-naïve, 25.6), 12 controls OFF Simple reward paradigm Reduced increase in activity in striatum and VTA for
increasing gamble-outcome value. Response to punishment
reduced in ventral putamen and PFC.
van Eimeren
et al.
2009 8 (L-Dopa 19.6, dopamine agonists
21.5, OFF 27.5)
OFF/ON/ON Gambling task ON L-Dopa and ON dopamine agonists both reduce VS
response to reward compared to OFF. Only ON dopamine
(continued on next page)
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Table 1 (continued )
Authors Year Participants (disease severity) Medication state Paradigm Main ﬁndings in patients with Parkinson's disease
agonists impaired OFC increase with reward prediction
errors.
Voon et al. 2010 14 ICD (H&Y 1.99), 14 non-ICD
(H&Y 2.35), 16 controls
OFF/ON Probabilistic learning task Dopamine agonists increase the rate of learning from gain
outcomes in ICD and led to an increased prediction error in
the VS. Additional differences between ICD and non-ICD for
gains and losses in striatum.
Voon et al. 2011 14 ICD (H&Y 1.91), 14 non-ICD
(H&Y 2.35)
OFF/ON Risk-taking task ICD patients with more risky choices and decreased
activation in OFC and ACC. Enhanced sensitivity to risk
along with decreased activation in the VS ON medication in
ICD patients but not non-ICD.
Resting state
Borchert 2016 33(ON 22.6), 76 controls ON DRT, OFF/
ON atom.
Resting state OFF atom. reduced rIFG connectivity with dorsal ACC, dlPFC
and left IFG. ON atom. increased rIFG-dorsal ACC
connectivity.
Cerasa, Koch
et al.
2015 12 LID (29.4), 12 non-LID (26.4) OFF/OFF to ON Resting state Levodopa-induced decreased IFG to M1 connectivity and
increased IFG to putamen connectivity in LID compared to
non-LID patients.
Esposito et al. 2013 20 drug-naïve (OFF 18.4, ON 10.7,
placebo 19.8), 18 controls
OFF/ON/
placebo
Resting state Levodopa-induced enhanced connectivity in SMA compared
to placebo. Regional changes in SMA correlate with motor
improvement.
Herz et al. 2016 12 LID (32.2), 12 non-LID (33.2) OFF/OFF to ON Resting state Levodopa-induced change in preSMA/SMA to putamen
connectivity correlated with LID severity. Levodopa-induced
change in putamen-M1 connectivity classiﬁed LID and non-
LID patients with high accuracy.
Structural imaging studies
Aarts et al. 2012 23 (OFF 26.3), 15 healthy controls OFF DAT SPECT
Task-switching with different
reward levels
Patients with stronger neurodegeneration in DS impaired in
task-switching and task-set maintenance.
Cerasa et al. 2011 36 LID (UPDRS total 20.0), 36 non-
LID (UPDRS total 23.5)
OFF – LID patients showed higher bilateral IFG volume compared
to non-LID patients.
Claassen et al. 2017 17 ICD (ON 15.5, OFF 25.8), 17
non-ICD (ON 23.7, OFF 32.9)
OFF/ON Arterial spin labeling Compared to non-ICD, dopamine agonists increased regional
blood ﬂow in VS in ICD patients, scaling with ICD severity.
Cilia et al. 2010 8 ICD (18.3), 21 non-ICD (20.2),
14 controls
ON DAT SPECT Reduced DAT in right VS in ICD compared to non-ICD
patients.
Payer et al. 2015 11 ICD (33.1), 21 non-ICD (28.1) ON PET Lower D2/D3 receptor density in VS in ICD patients,
correlating with ICD severity.
Smith et al. 2016 320 non-ICD at baseline (21.2), 54
developed ICD
ON DAT SPECT Greater decrease in DAT availability in right caudate and
mean striatum as risk-factors for ICD.
Voon et al. 2014 15 ICD (H&Y 3.0), 15 non-ICD
(H&Y 3.0)
ON DAT SPECT Reduced DAT in right striatum in ICD compared to non-ICD
patients.
Vriend et al. 2014 31 non-ICD at baseline (baseline:
later developing ICD (n¼ 11) 26.3,
non-ICD (n¼ 20) 19.2)
OFF DAT SPECT Reduced DAT availability in right VS, anterior DS and
posterior putamen in ICD compared to non-ICD. DAT
availability in right VS and anterior DS correlated negatively
with ICD severity.
Studies are listed in alphabetical order in each section. Studies are fMRI studies if not otherwise mentioned. Disease severity in parentheses in third column is Uniﬁed
Parkinson's Disease Rating Scale motor subscale score if not otherwise mentioned.
Abbreviations: ACC anterior cingulate cortex, atom. atomoxetine, BG basal ganglia, CMA cingulate motor area, dlPFC dorsolateral PFC, DRT dopamine replacement
therapy, DS dorsal striatum, GPe globus pallidus external, H&YHoehn& Yahr stage, ICD impulse control disorder, IFG inferior frontal gyrus, IPC inferior parietal cortex,
LID levodopa-induced dyskinesia,M1 primary motor cortex, MFC middle frontal cortex, MFGmiddle frontal gyrus, OFC orbitofrontal cortex, PFC prefrontal cortex, PM
premotor cortex, Pre-SMA pre-supplementary motor area, SMA supplementary motor area, SN substantia nigra, SPC superior parietal cortex, STN subthalamic nucleus,
UPDRS Uniﬁed Parkinson's Disease Rating Scale, vlPFC ventrolateral PFC, VS ventral striatum, VTA ventral tegmental area.
Fig. 1. Convergence of activation maxima for the comparison between PD patients off medication and healthy controls reported in previous functional
neuroimaging studies during motor tasks. Activation differences were consistently observed in M1 (A), a cluster spanning preSMA and SMA (B), superior parietal
lobule (C), inferior parietal cortex (D) and posterior putamen (E). Activation of posterior putamen was also consistently increased by dopaminergic medication and
correlated with differences in PD severity across studies (not shown, see Herz et al., 2014b for more details).
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D. Meder et al. NeuroImage 190 (2019) 79–93pre-supplementary motor area (preSMA1) was different between PD
patients and controls but did not signiﬁcantly differ in PD patients on
and off medication.
While activation differed from healthy controls, the direction of task-
related activity changes varied across studies. Some studies showed in-
creases in task-related motor activation, whereas other studies showed
decreases relative to healthy controls. Why do changes in task-related
cortical activation differ so strongly across studies? One reason could
be that task performance varied between studies, inﬂuencing the
observed activity patterns. Most studies tried to match performance in
both groups by using relatively simple motor tasks (e.g. cued button
presses or ﬁnger tapping). However, more subtle measures such as peak
force, peak movement acceleration, smoothness or stability of movement
trajectories might reveal differences. While such detailed neuroimaging
studies of subtle behavioural differences in bradykinesia are still amiss,
Buhmann et al. (2003) shed some light onto the neural mechanisms
underlying bradykinesia by relating changes in neural activity to changes
in clinically relevant behaviour. During fMRI acquisition patients and
healthy controls performed a ﬁnger tapping task once off medication and
then after intake of the dopamine precursor levodopa, while dopamine
levels gradually increased. In the OFF-medication state, task-related
activation of the hand area of M1 in the more affected hemisphere was
decreased compared to the less affected hemisphere. In addition, motor
activation of M1 and SMA was reduced relative to healthy controls.
Levodopa intake increased motor activation of M1 and SMA in the most
affected hemisphere compared to the OFF-medication state. The
levodopa-induced activation of M1 correlated strongly with the indi-
vidual improvement in movement performance. In a subgroup of patients
this correlation was also found in caudal SMA. These results suggest that
the dopamine-induced activation increase in M1 and SMA is directly
related to improvement in bradykinesia. In that study, the ﬁeld-of-view
did not cover the basal ganglia, therefore levodopa-related changes in
putaminal activity and its correlation with bradykinesia could not be
evaluated. However, several neuroimaging studies have provided evi-
dence that the putamen is related to movement vigour in PD. Spraker
et al. (2010) demonstrated that putaminal activity is decreased in
drug-naïve PD patients compared to healthy controls during a precision
grip-force task. In line with this, Kraft et al. (2009) showed decreased
putaminal activity during grip force production in PD patients off
medication compared to healthy controls, which signiﬁcantly increased
after dopamine intake. Finally, a H2O-PET study revealed a close rela-
tionship between increases in movement velocity and putaminal activity
in PD patients during a visuo-manual tracking task (Turner et al., 2003).
A resting-state fMRI study also suggested the SMA as a core target of
dopaminergic medication in PD (Esposito et al., 2013).
Together, these results suggest that a cortico-subcortical network
including SMA, M1 and putamen is closely related to modulations of
movement vigour and that physiological function of this network seems
to critically depend on dopamine.2.2. Involuntary movements: dyskinesia
Even though bradykinesia is a core feature of PD, many patients come
to exhibit a seemingly opposite behaviour with constant, purposeless
movements making patients appear restless or ﬁdgety (Edwards et al.,
2008). This phenomenon is termed dyskinesia or levodopa-induced1 SMA and preSMA lie directly adjacent in the superior frontal gyrus in
Brodman area (BA) 6 (Picard and Strick, 2001). SMA is mainly interconnected
with other premotor and motor areas as well as the spinal cord (Muakkassa and
Strick, 1979; Picard and Strick, 2001). Conversely, preSMA is interconnected
with prefrontal areas (Nachev et al., 2008; Picard and Strick, 2001). Following
Johansen-Berg et al. (2004) and Picard and Strick (2001), we assign activations
located anterior to the vertical commissure anterior (VCA) line, i.e. anterior to
y¼ 0, to the preSMA and activation posterior to VCA to the caudal SMA proper.
83dyskinesia, since it is typically observed after levodopa intake (Nutt,
2008). Dyskinesia is one of the most frequently observed side effects of
dopamine replacement occurring in ~40% of patients after 4–6 years of
PD (Ahlskog and Muenter, 2001; Cilia et al., 2014). Most commonly,
patients are dyskinetic when levodopa levels reach their peak (‘peak-dose
dyskinesia’) and their dyskinesia gradually disappears when levodopa
levels decrease. Affected patients may ﬂuctuate between hypokinetic
(bradykinesia) and hyperkinetic (dyskinesia) states. In terms of patho-
physiology, the aberrant dyskinetic response to levodopa therapy is
driven by the progressive failure of cellular re-uptake and recycling of
striatal dopamine, leading to ﬂuctuating dopamine levels (Cenci and
Lundblad, 2006; Troiano et al., 2009). While bradykinesia indicates
deﬁcient vigour to move in a dopamine depleted state, dyskinesia might
be related to an excessive enforcement of movement vigour in the
dopamine repleted state (Hallett and Khoshbin, 1980; Ingvarsson et al.,
1997; Wenzelburger et al., 2002).
Until recently there was a paucity of imaging studies in PD patients
with dyskinesia, in part because patients’ involuntary movements cause
severe fMRI artefacts, affecting data quality. Another methodological
problem is that the comparison of dyskinetic patients with non-
dyskinetic patients may result in a stronger activation of motor areas
due to the vigorous (but involuntary) movements of the dyskinetic pa-
tients in the scanner (Rascol, 1998; Brooks, 2000).
To circumvent these problems, new neuroimaging paradigms have
compared patients who are prone to dyskinesia with patients unaffected
by dyskinesia, in an off-medication state where neither is currently
dyskinetic. The underlying assumption that PD patients affected by
dyskinesia display abnormal functional brain patterns even in a non-
dyskinesia state is supported by behavioural studies (e.g. Stevenson
et al., 2014, 2011). Cerasa et al. (2012) found that patients with dyski-
nesia showed stronger activation in preSMA and decreased activation in
the right inferior frontal gyrus (IFG) during self-initiated and externally
triggered movements. Task-related activity in preSMA during both tasks
correlated positively with dyskinesia severity. In contrast, IFG activity
correlated negatively with dyskinesia severity. In a morphometric study,
they found that IFG grey matter volume was signiﬁcantly larger in
dyskinetic versus non-dyskinetic patients (Cerasa et al., 2011).
These studies revealed abnormalities in dyskinetic patients, but not
the role of dopamine. To address this question, Herz et al. (2014c)
studied patients with and without dyskinesia after prolonged withdrawal
of dopaminergic medication and immediately after levodopa intake.
Patients performed a Go-NoGo task, until dyskinesia emerged. This
pharmacodynamics fMRI approach traced the gradual change in neural
activity, while dopamine levels increased but before the onset of dyski-
nesia. The change in neural activity immediately (<25min) after levo-
dopa intake was signiﬁcantly stronger in the preSMA and the bilateral
putamen in patients who later developed dyskinesia compared to patients
who did not. This difference was speciﬁc to NoGo response inhibition
trials. Furthermore, the activity change in preSMA was strongly corre-
lated with the severity of dyskinesia that later emerged. The analysis of
dopamine-induced changes in effective connectivity in the motor
network (Herz et al., 2015) showed that an early change in connectivity
from putamen to M1 was only observed in patients with dyskinesia. This
change in connectivity from putamen to cortical areas was correlated
with out-of-scanner dyskinesia severity.
Even in the resting state, the change in connectivity between pre-
SMA/SMA and putamen after levodopa in dyskinetic patients correlated
with the severity of emerging dyskinesia. The change in connectivity
accurately predicted whether a patient would develop dyskinesia or not
(Herz et al., 2016). Importantly, the link between resting-state connec-
tivity and the manifestation of dyskinesia only emerged when consid-
ering the dopamine-induced change in connectivity. Neither connectivity
estimates derived from the off-medication state alone nor from the
on-medication state alone could distinguish between dyskinetic and
non-dyskinetic patients. Cerasa et al. (2015b) found that resting-state
connectivity decreased between IFG and M1 and increased between
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without (Cerasa et al., 2015b). Dyskinesia severity correlated negatively
with connectivity changes between IFG and M1, and positively with
connectivity changes between IFG, the putamen and STN.
These studies link two cortico-subcortical networks to dopamine-
induced involuntary dyskinesia movements: a prefrontal network
comprising IFG and preSMA and a caudal motor network comprising M1
and SMA along with their striatal connections. The preSMA and IFG may
be recruited in order to suppress emerging dyskinesia (Aron and Obeso,
2012; Cerasa et al., 2015c; Rothwell and Obeso, 2015), since they are
critically involved in other aspects of motor inhibition (Aron et al., 2016;
Rae et al., 2014; Ridderinkhof et al., 2011). The ability of the prefrontal
network to suppress dyskinetic movements might explain some of the
differences in dyskinesia severity. However, this interpretation remains
speculative. Given the correlative nature of previous studies, it remains to
be elucidated whether activation of prefrontal networks during dyski-
nesia constitutes a compensatory mechanism or might, in contrast, be
involved in the generation of involuntary movements. These hypotheses
could be tested by combining transcranial magnetic stimulation (TMS) to
perturb cortical areas and mapping its effect on neural activity using
fMRI. For example, TMS over SMA has beneﬁcial - albeit moderate and
short lasting - effects on dyskinesia (Brusa et al., 2006; Koch et al., 2005),
but it remains unclear whether this is due to local suppression of SMA
activity or modulation of interconnected neural areas (see e.g. Herz et al.,
2014a; Obeso and Strafella, 2014).
A general shortcoming of many neuroimaging studies in dyskinesia is
the prevalence of simple movement tasks and gross measures of behav-
iour. A notable exception is the assessment of behavioural inhibition
using the stop-signal reaction time (SSRT) by Cerasa et al. (2015a). Pa-
tients with dyskinesia had higher activity in the SMA during commission
errors and lower activity in right IFG during successful inhibition after
dopamine intake, compared to patients without dyskinesia. Such
‘behaviourally-driven’ neuroimaging studies are particularly useful
(Krakauer et al., 2017).
In summary, neuroimaging studies in PD assessing motor execution
indicate that dopamine modulates pathways connecting M1 and SMA
with the basal ganglia for the enforcement of motor vigour. It remains to
be shown whether the activation of prefrontal networks is related to
compensatory inhibitory mechanisms contributes to the generation of
involuntary movements.
3. Non-motor symptoms in PD
Dopaminergic neurons in the VTA project mainly to ventral (‘limbic’)
striatum. The antero-dorsal ‘associative/cognitive’ striatum receives
input from both SN and VTA (Haber, 2003). Although VTA neurons are
less affected by neurodegeneration (Kish et al., 1988), cognitive func-
tions associated with the mesolimbic (VTA-striatum) and mesocortical
(VTA-cortex) pathways are also impaired in PD (Robbins and Cools,
2014). This may reﬂect phasic dopamine release in ventral striatum that
codes prediction error during learning (Schultz, 2017), and dopamine's
contribution to risk assessment, effort evaluation and motivational drive
(e.g. Christopoulos et al., 2009; Niv et al., 2007; Schultz, 2015). There-
fore, PD and the impact of dopaminergic treatment have been used to
investigate the effects of changing dopamine levels on this area of
cognition. In this section, we discuss what has been learned from fMRI
about the involvement of dopamine in cognitive ﬂexibility, reward pro-
cessing and learning mechanisms, both in PD as well as in the healthy
brain. We also consider how other neurotransmitter systems e.g. alter-
ations in noradrenergic neurotransmission contribute to cognitive deﬁ-
cits in PD and interact with dopamine.
3.1. Cognitive and behavioural ﬂexibility
3.1.1. Switching between tasks and actions
Cognitive ﬂexibility enables one to balance between maintaining84behaviour that is overall advantageous in spite of occasional negative
outcomes and switching behaviour when the rules of the environment
have changed. Task performance can require shifts between cognitive
strategies or the use of different response rules. A seminal study on
cognitive ﬂexibility in PD was conducted by Cools et al. (2007). The
study was important because it tested an inﬂuential idea: that the rela-
tionship between the level of striatal dopaminergic innervation and
optimal neural processing in the striatum is characterized by an inverted
U-shaped Yerkes-Dodson function (Arnsten et al., 1994; Cools, 2006;
Cools et al., 2001; Robbins, 2000). Assuming an inverted U-shaped
relationship between dopamine levels and cognitive function, the
prominent nigrostriatal neurodegeneration causes a leftwards shift on
the inverse U-shaped curve away from the optimum for those cognitive or
motor functions that are mediated by the SN-dorsal striatum pathway
(Fig. 2). This leftward shift can be reversed by dopamine replacement
therapy. At the same time, dopamine “replacement” leads to relative
“dopamine overdosing” in the less-affected ventral VTA-striatal (‘limbic’)
circuitry and anterior dorsal nigro-striatal (‘associative/cognitive’) cir-
cuitry. This relative excess in dopamine in the ONmedication state would
result in a rightward shift towards the descending part of the U-shaped
curve, causing suboptimal circuit function with adverse effects on
cognition (Cools, 2006; Cools et al., 2001, Fig. 2).
Cools et al. (2007) used a probabilistic reversal learning task which
required patients on two days (ON and OFF medication) to choose be-
tween two abstract visual stimuli, receiving subsequent feedback about
the correctness of their choice. One of the stimuli was the correct choice
in most trials, while the other one most often was the incorrect choice. At
several points throughout the experiment, this association was reversed
without informing the participants about the reversal of outcome prob-
abilities. There were no consistent dopaminergic effects on behaviour or
regional activity in dorsal striatum. Yet dopamine replacement reduced
the BOLD response in the ventral striatum to “ﬁnal” reversal errors, i.e.
errors which were followed by a switch in choice behaviour in the next
trial. Neural activity evoked during these events reﬂects a multitude of
processes, including neural processing of negative feedback, the decision
to switch behaviour and the expectation of reward in the subsequent
trial. While it is not clear which of these cognitive processes are mediated
by the ventral striatum and modulated by medication, the results do
suggest dopaminergic involvement of ventral (but here not dorsal)
striatal areas in reversal-related behaviour (Cools et al., 2007).
Rowe et al. (2008) also examined different aspects of cognitive ﬂex-
ibility in a task where participants had to detect targets comprising
combinations of spatial or verbal cues, with three consecutive correct
detections leading to a reward. In short, the task involved set-shifting,
between spatial and verbal domains to detect targets, and reward
expectation. There was no direct effect of medication on task perfor-
mance, but task-related activation of the right mid-caudate and left
ventrolateral PFC (vlPFC) activity increased in proportion with task
performance in a non-linear U-shaped manner depending on disease
severity. The peak of this U-curve shifted dependent on the state of
medication (OFF or ON). Similar shifts in the U-shaped relationship be-
tween disease severity and neural activity changes were found in the
anterior cingulate cortex (ACC) for anticipating and receiving a reward.
The results support the hypothesis that differences in the amount of
dopaminergic neurodegeneration among dorsal and ventral basal ganglia
circuits cause differential responses in these circuits to dopamine
replacement. A medication-induced increase in dopamine levels shifts
performance towards optimum in one of the circuits, but away from
optimum in another circuit (Rowe et al., 2008). Interestingly, medial
frontal responses to reward expectation were diminished in patients, but
their response to actual (unexpected) reward was enhanced.
Aarts et al. (2014) investigated the involvement of the ventral and
dorsal striatum pathways on reward expectation and task-switching.
Patients were studied with fMRI in the ON and OFF medication state,
while they had to respond to an arrow pointing left or right and the words
“left” or “right” shown inside the arrow. The symbol and word stimulus
Fig. 2. "Overdosing theory" describing the restoration of optimal dopa-
mine levels for performance of some tasks and overdosing for others.
Depending on the degree of neurodegeneration, performance in different tasks is
impaired to different degrees by the disease. Dopaminergic treatment can then
restore dopamine levels to an optimum in the SN-posterior dorsal striatum
pathway responsible for the motor symptoms, but leads to relative “overdosing”
of the VTA-ventral striatum pathway showing less neurodegeneration, impairing
performance. For simplicity, only two hypothetical midbrain-striatal pathways
are depicted, but it should be noted that other networks (including cortical-
subcortical networks) might be affected to different degrees and show
different shapes of the inverse U-shaped curves (e.g. more ﬂat, more peaked, or
skewed). In some tightly controlled laboratory situations, the “normal” dopa-
minergic tone in the healthy brain might even result in performance positioned
away from the curve's optimum, such that neurodegeneration or dopamine
administration unexpectedly might improve performance (e.g. MacDonald
et al., 2011).
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rection. Participants were cued in each trial to either indicate the arrow
direction or the direction described by the word, requiring task-switching
in 50% of trials. The study revealed a differential effect of dopaminergic
medication on ventral and dorsal activity in the striatum depending on85the cognitive process involved. Dopaminergic medication attenuated the
response of ventral striatum to reward anticipation where stronger
attenuation was associated with a higher beneﬁt of reward anticipation
on task performance in the ON compared to the OFF medication state. In
the dorsal striatum, the more dopamine increased regional activity dur-
ing task-switching, the more patients showed an improvement in
task-switching performance in the ON medication state (location of peak
activity changes was not reported). The effect of dopaminemedication on
task-related activity and its effects on task-switching behaviour ﬁt well to
the idea that dopamine medication can not only restore the motor
symptoms of PD but also cognitive functions that are subserved by the
anterior-dorsal striatum.
The same task was used in a separate group of PD patients in which
the extent of striatal dopaminergic neurodegeneration was assessed with
dopamine transporter (DAT) Single Photon Emission Computed To-
mography (SPECT) (Aarts et al., 2012). Patients with stronger neuro-
degeneration in the posterior dorsal “motor” striatum performed worse
in balancing between switching tasks and repeating the same task in-
structions (continuous behaviour in spite of distracting information),
again highlighting the importance of the dorsal striatum for ﬂexible ac-
tion selection (Aarts et al., 2012).
While both studies by Cools et al. (2007) and Aarts et al. (2014)
investigated task-switching, the former study found an effect in the
ventral striatum, but the latter study in the dorsal striatum. In the study
by Cools et al. (2007), the main analyses were based on the event-related
responses to the ﬁnal reversal error, reﬂecting a mixture of cognitive
processes. In contrast, the experimental paradigm employed by Aarts
et al. (2014) dissociated more rigorously reward anticipation from
task-switching and thus may reﬂect more speciﬁcally activity related to
switching.
Two additional studies investigated action selection, contrasting
externally cued and freely chosen actions (Hughes et al., 2013, 2010).
Depending on the speciﬁc experimental design, dopaminergic medica-
tion led to an increase or a decrease in perseveration (choosing to move
the same ﬁnger as in the previous trial). The pattern of results suggested
“overdosing” in less severely affected patients with less dopamine
depletion, but a recovery of function in more severely affected patients.
These behavioural patterns were associated with corresponding activity
changes in bilateral body and tail of the caudate nucleus as well as right
vlPFC (Hughes et al., 2013, 2010).
The role of dopamine in action selection may also be revealed by
examination of the effects of COMT polymorphisms, which lead to
chronic variations in frontal cortical dopamine and correspondingly to
changes in activity in response planning (Fallon et al., 2013; Nombela
et al., 2014b) and response selection (unpublished). But, these poly-
morphisms also inﬂuence brain structure in development and adulthood,
including the same prefrontal cortical regions (Rowe et al., 2010), sug-
gesting possible effects of dopamine on long-term cortical plasticity as
well as acute neurotransmission.
In summary, these studies showed that delicate optima of dopamine
levels are required for optimal cognitive and behavioural ﬂexibility. They
also suggest that dopamine exerts its effect on cognitive ﬂexibility in the
human brain through non-linear modulation of task-related neural ac-
tivity in striatal (especially the anterior-dorsal striatum) as well as pre-
frontal cortical regions. The relationships between dopamine levels,
regional task-related brain activity, and optimal cognitive function can
be described by as inverse U-shaped curve. The optimal dopamine level
(i.e. the peak of the inverse U-shape curve) depends on how much the
various striato-thalamo-cortical circuits are affected by dopaminergic
denervation and thus reﬂects the dorsoventral gradient of striatal
neurodegeneration.
3.1.2. Impulsivity and inhibitory control
A critical aspect of cognitive and behavioural control is the ability to
inhibit actions. While inhibition may facilitate task-switching (above),
recent studies have indicated catecholaminergic moderation of different
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tasks with competing response options, either by simultaneously pre-
senting cues that can be congruent or incongruent with regard to the
associated action (e.g. Stroop task), by having some repeatedly cued
prepotent response that has to be restrained on the occasion of another
rarely cued response (e.g. GoNogo task) or by cancelling an action after it
has been initiated (e.g. stop-signal task).
When patients with PD performed a complex task with congruent and
incongruent target stimuli, response facilitation by congruent cues (i.e., a
shortening of reaction times) was reduced in the ON compared to the OFF
medication state (MacDonald et al., 2011). Yet the interference effect of
incongruent cues (i.e. prolongation of reaction times) was enhanced by
medication, revealing that dopamine replacement impaired performance
in both trial types. Interestingly, the increase in interference by incon-
gruent cues induced by dopamine medication brought patients’ perfor-
mance to a similar level of interference as seen in healthy controls,
whereas patients off medication were performing better than healthy
controls. The authors suggested that patients off medication were
impaired in integrating the conﬂicting information in the incongruent
task condition which in this speciﬁc task actually gives them an advan-
tage in terms of reaction times. In a separate experiment, healthy controls
performed the task inside the MRI-scanner, revealing ventral striatal
activity associated with congruent trials and anterior dorsal striatal ac-
tivity associated with incongruent trials. This is compatible with the
hypothesis that the behavioural effects seen in the patient group are due
to an overdosing of the ventral striatum (impaired facilitation) but the
recovery of dorsal striatum function (MacDonald et al., 2011).
The type of inhibition required for cancellation of a task is distinct
from inhibition of inappropriate response tendencies during action se-
lection and commonly studied with a stop-signal task, in which a pre-
potent Go action has to be cancelled. Critically, the cancellation cue is
given after the Go cue, and by varying the delay, one can chart the
inhibitory response function or standardise performance in every
participant (at say 50% successful stopping). Performance on such stop-Fig. 3. Noradrenaline and inhibition. A. The inferior frontal gyrus (IFG) activat
increases activation of IFG, versus placebo, but variability about the main effect o
diffusivity of frontostriatal pathways (blue) correlates with the impulsivity (SSRT). D
(M1) and subthalamic nucleus (STN) indicates synergistic interactions between the p
STN connectivity, in proportion to disease severity. Patients were on their usual dop
with permission.
86signal tasks is not affected by dopamine treatment in drug naïve patients,
or dopamine withdrawal (Nombela et al., 2014a; Obeso et al., 2011).
However, the task and its associated neural systems, are affected by drugs
with joint dopaminergic and noradrenergic effects such as methylphe-
nidate. Moreover, the neurodegeneration of noradrenergic neurons in the
locus coeruleus precedes dopaminergic neurodegeneration in the SN in
PD (Braak et al., 2003; Hawkes et al., 2010). This has led to a recent focus
on the noradrenergic role in inhibitory control (Borchert et al., 2016; Rae
et al., 2016; Ye et al., 2015). Even though the focus of this article is on the
dopaminergic system, these studies are relevant because they use PD as a
model disease to provide insights into the importance of the noradren-
aline system in inhibitory control in the healthy brain, and the in-
teractions between noradrenergic and dopaminergic signalling.
In an fMRI study, PD patients performed a combined GoNogo/stop-
signal task on the noradrenaline reuptake inhibitor atomoxetine (or
placebo) while on their usual dopamine medication (Ye et al., 2015). On
Placebo, patients had longer SSRT (poorer inhibitory control), lower
activity related to successful stopping in the right IFG and weaker func-
tional connectivity between the right IFG and striatum compared to
healthy controls (Fig. 3a). Individual improvements in SSRT on atom-
oxetine were correlated with a stronger increases in right IFG activity,
right IFG-striatum functional connectivity and greater structural fron-
tostriatal connectivity (Fig. 3b and c; Ye et al., 2015). A second study
used a similar experimental design in a separate group of participants
(Rae et al., 2016). On placebo, patients again had longer SSRT and
showed less activity for successful stopping in right IFG, but also preSMA,
putamen and STN. Atomoxetine signiﬁcantly increased striatal activity
during successful stop trials. Furthermore, patients on placebo lacked
connectivity between preSMA and IFG: this connection was restored by
noradrenergic reuptake inhibition. The pre-SMA and IFG interacted
synergistically in their inﬂuence on the STN, and the higher the atom-
oxetine blood-plasma levels the stronger this interaction (Fig. 3d and e;
Rae et al., 2016). The medication-induced improvement in performance
correlated with structural connectivity of the IFG. Despite the emphasision on successful stop-trials is reduced in PD, versus controls. B. Atomoxetine
f drug is driven by disease severity as measured by the UPDRS. C. The mean
. Dynamic causal modelling of the interactions among IFG, SMA, motor cortex
rojections from SMA and IFG to the STN. E. Atomoxetine modulates the IFG to
aminergic medication at all times. From Rae et al. (2016) and Ye et al. (2015)
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predicted in part by the patients’ levodopa dose equivalent (Ye et al.,
2016), in keeping with an interaction between these two neurotrans-
mitter systems. Similar effects of atomoxetine (versus placebo) on right
IFG connectivity to medial prefrontal cortex have been observed in
resting-state fMRI of patients with PD (Borchert et al., 2016).
Together, these results suggest an impairment in inhibitory control in
PD patients even when they are on their dopamine medication: these
impairments could be relieved by noradrenergic treatment in a subset of
patients. Since the locus coeruleus undergoes marked and early degen-
eration in PD (Braak et al., 2003; Hawkes et al., 2010), these studies
highlight the importance of noradrenergic projections from the locus
coeruleus to prefrontal cortex and interactions with dopamine systems
for the adequate inhibitory control of actions.
Complementing the work on the noradrenergic system, some neuro-
imaging studies showed a strong association between neurodegeneration
in the cholinergic network and the severity of cognitive symptoms and
the development of dementia in PD (Gratwicke et al., 2015; Gratwicke
and Foltynie, 2018; Kehagia et al., 2013). Together, these studies reveal
the importance of taking into account the degeneration of
non-dopaminergic neurotransmitter systems. Future studies should
therefore consider combined manipulation of several transmitters to
scrutinize their combined effects on cognition.
In summary, the weight of evidence is for dopaminergic modulation
of action evaluation (including reward) and selection (including task
switching) but primarily non-dopaminergic modulation of response in-
hibition per se. The study by MacDonald et al. (2011) tentatively suggests
an overdosing of ventral striatum (impairing facilitation) and a restora-
tion of information integration in anterior dorsal striatum (increasing the
incongruency effect) with dopamine medication. Consequently, these
results suggest dopaminergic involvement in inhibition and conﬂict
resolution in ventral and dorsal striatum in the healthy brain. However,
this is only indirect evidence at best and shows the need for further
studies directly investigating dopaminergic modulation of inhibitory
control. Together, these studies corroborate the importance of optimal
noradrenaline levels (likely mediated by the locus coeruleus) in a cir-
cuitry centred on right IFG and additionally pre-SMA, caudate and STN
(Borchert et al., 2016; Rae et al., 2016; Ye et al., 2015).
3.2. Reward, punishment and learning
Dopamine neurons in the VTA are relatively spared in PD, but func-
tionally relevant changes occur in this circuit as well, affecting its core
functions in reward, prediction error coding and learning. We discuss
imaging studies in PD investigating neural changes to reward and pun-
ishment and what these types of studies can reveal about the neural
correlates of reinforcement learning in the diseased and healthy brain.
Van der Vegt et al. (2013) studied reward and punishment encoding
in de novo PD patients who had just been diagnosed but not yet begun
dopamine treatment. This provided the unique opportunity to investigate
the effects of dopamine neuron degeneration before the system had
adapted to long-term dopamine treatment. In a simple gambling para-
digm, subjects chose one of two cards and received either high or low
monetary reward or punishment with a ﬁxed probability of 50%. Re-
wards and punishments occurred simply by chance, without learning
card-reward associations. In healthy participants, there was a linear in-
crease in BOLD activity with outcome value (from high losses, low losses,
low wins to high wins) in a large network of brain regions, including
ventral and dorsal putamen, caudate and VTA. Brain activity associated
with winning was reduced in PD patients in dorsal putamen, caudate and
VTA, amongst others. The functional response to punishments was also
reduced in PD patients in the ventral putamen and prefrontal cortex (van
der Vegt et al., 2013). In line with the neurodegeneration of the dopa-
minergic projections from VTA to ventral striatum (Alberico et al., 2015),
these ﬁndings highlight that the encoding of reward and punishment is
affected in PD and is already evident at the time of clinical diagnosis.87While much of the BOLD activity in the study by Van der Vegt et al.
(2013) was most likely related to the processing of prediction errors,
there was no learning involved in task performance. Prediction errors
are, however, used in order to update one's estimation of the future
likelihood of success and are often investigated in the context of rein-
forcement learning in tasks that allow learning from the outcome of one's
actions in order to maximize reward and minimize punishment. An
inﬂuential study by Frank et al. (2004) introduced the notion that rein-
forcement learning from prediction errors elicited by positive and
negative outcomes is affected by dopamine depletion and dopamine
replacement therapy in a predictable manner. Dopaminergic medication
was proposed to increase D2 receptor inhibition in the indirect NoGo
pathway and thus to lead to a decrease in learning from punishment. At
the same time, medication-induced activation of D1 receptors in the
direct pathway should facilitate learning from reward. In accordance
with these predictions, in the dopamine depleted OFF state, patients
tended to learn relatively more from punishment compared to reward.
Dopamine medication then shifted that balance towards the opposite
pattern where they learned more from reward compared to punishment.
Some studies found results that at least partially supported this ﬁnding
(Bodi et al., 2009; Maril et al., 2013; Palminteri et al., 2009; Rutledge
et al., 2009; Schmidt et al., 2014), but most other studies have actually
found dopaminemedication to affect choice behaviour after learning, but
not the learning itself (Coulthard et al., 2012; Grogan et al., 2017; Shiner
et al., 2012; Smittenaar et al., 2012). This post-learning effect might be
attributed to repeated dopamine release in VTA-hippocampal and
VTA-striatum connections affecting longer-term memory (Bethus et al.,
2010; Calabresi et al., 1997). Another study by Timmer et al. (2017)
suggested that depression, a frequent non-motor symptom of PD
(approximately 35%, Reijnders et al., 2008), may explain differences in
reward learning, at least when learning from punishing stimuli.
Crucially, one recent study (Grogan et al., 2017) carefully replicated the
study by Frank et al. (2004) and failed to ﬁnd any effects of disease or
medication.
Only a few studies on learning from reward and punishment have
acquired fMRI data. Shiner et al. (2012) found that dopaminergic
medication only affected neural activity for choice during recall after the
learning phase, but not for prediction errors during learning. During
recall, ventromedial prefrontal cortex (vmPFC) and ventral striatum
signiﬁcantly increased their activity with the value of the chosen option
ON, but not OFF dopaminergic medication (but note that the authors did
not test those effects directly against each other). Similarly, Rowe et al.
(2008) found less ACC activation with increasing disease severity sug-
gestive of a failure of reward prediction (anticipation) rather than
insensitivity to reward per se. In another study, medication and inter-
estingly also placebo reduced reward prediction error responses in the
ventral striatum and increased vmPFC activity for the value of rewarding
options (Schmidt et al., 2014). At ﬁrst sight, the decrease in prediction
error activity in the ventral striatum in the ON state might seem sur-
prising. However, given the complex compensatory response of dopa-
mine receptors to changes in dopamine levels (Navntoft and Dreyer,
2016), it is unclear how a putative “overdosing” of ventral striatal
dopamine levels affects the prediction error signal. Another study used a
gambling task not involving learning (previous outcomes were not useful
for predicting future outcomes), but still allowing the calculation of
prediction errors (van Eimeren et al., 2009). They found that the
response to rewarding outcomes was signiﬁcantly reduced by levodopa
and dopamine agonist treatment in the ventral striatum. Only three
studies, including the two imaging studies by Shiner et al. (2012) and
Schmidt et al. (2014), used reinforcement learning models to investigate
changes in the learning rate. The learning rate is a central parameter
assumed to govern adaptive reinforcement learning since it scales the
extent to which a reward prediction error for the outcome of a given
choice adjusts one's estimate of future success for that choice. Depending
on the (in-)stability of the probabilities generating outcomes, one should
adapt the learning rate in order to optimally learn from outcomes and
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2017; Nassar et al., 2010). Thus, it is an interesting question whether the
disease itself or dopamine replacement therapy cause changes in adap-
tive scaling (i.e. the learning rate), potentially impairing optimal
learning. Given that phasic increases in dopamine neuron ﬁring code the
magnitude of the prediction error (Schultz, 2017), it might be expected
that dopaminergic medication would increase this prediction error
magnitude. In the reinforcement learning model, this might be reﬂected
in an increased learning rate parameter which scales the magnitude.
While Shiner et al. (2012) did not ﬁnd effects of medication on the
learning rate, Rutledge et al. (2009) found the predicted increase in
learning rate in the ON condition compared to OFF. Additionally, when
modelling separate learning rates for rewarding and punishing outcomes,
only the learning rate for rewarding outcomes was increased by medi-
cation. While being in line with the proposed hypotheses, the results do
not show that the effect is actually due to an upscaling of prediction error
magnitude by dopaminergic medication. Dopamine replacement is
thought to increase baseline ﬁring whereas the prediction error is coded
by a phasic dopamine signal. An up-scaling of prediction error magnitude
also does not conform with the reduced ventral striatum response to
prediction errors under medication reported by Schmidt et al. (2014) and
van Eimeren et al. (2009).
Interestingly, Schmidt et al. (2014) found that placebo medication
signiﬁcantly increased the learning rate compared to the OFF state. This
study reported several behavioural and neural differences in the placebo
condition compared to the OFF-medication state. The placebo effects
further complicate the interpretation of changes in behaviour and neural
activity resulting from manipulations of the dopaminergic state in PD.
The expectation of dopaminergic treatment may lead to an endogenously
mediated increase in dopamine levels comparable to actual medication.
In summary, despite rather clear theoretical predictions about the
effects of dopaminergic neurodegeneration and medication on excitatory
and inhibitory basal ganglia pathways for learning and a ﬁrst study
ﬁnding according behavioural results (Frank et al., 2004), subsequent
behavioural and imaging data did not provide clear support (Coulthard
et al., 2012; Grogan et al., 2017; Shiner et al., 2012; Smittenaar et al.,
2012). If anything, due to unknown mechanisms, dopaminergic medi-
cation seems to lead to a reduction of prediction error coding in ventral
striatum (Schmidt et al., 2014; van Eimeren et al., 2009). Tonic dopa-
mine levels, especially in ventral striatum, have also been suggested to
modulate the motivation to exert effort in order to obtain rewards (e.g.
Collins and Frank, 2014; Niv et al., 2007; Walton et al., 2006). However,
while some studies have found effects of PD and dopaminergic medica-
tion on effort taking (Chong et al., 2015; Le Heron et al., 2018), another
group found tonic dopamine levels to affect reward- but not
effort-learning (Skvortsova et al., 2017).
The ﬁndings also highlight the complex interplay of tonic dopamine
levels changed by disease and medication on the one hand and the phasic
signals involved in reinforcement learning on the other hand.
3.2.1. Reward and punishment in PD patients with ICDs
In recent years, impulse control disorders (ICD) have come into the
focus of Parkinson-related research. There is a wide continuous spectrum
of impulsive behaviours in PD (Nombela et al., 2014a), but a sub-group of
approximately 15% of patients develop a severe ICD as a result of disease
and dopamine replacement therapy (Weintraub et al., 2010). These ICDs
include pathological gambling, compulsive shopping, binge eating or
compulsive sexual behaviours (Schreiber et al., 2011). It has been sug-
gested that PD patients developing ICDs are especially vulnerable to
ventral striatal “overdosing” (Cilia and van Eimeren, 2011). The inves-
tigation of this sub-population of PD patients has provided further in-
sights into the difference in optimal dopamine levels in different
cortico-basal ganglia circuits.
PET and SPECT studies have generally support the hypothesis that
PD-ICD patients show a stronger overdosing in ventral striatum due to
medication. There is decreased dopamine transporter (DAT) availability88in the ventral striatum of patients with ICDs, suggesting a reduced
dopamine clearance from the synaptic cleft, amplifying the overdosing
effect of dopaminergic medication (Cilia et al., 2010; Voon et al., 2014).
Decreased DAT availability in different striatal regions are a risk factor
for developing ICDs (Smith et al., 2016; Vriend et al., 2014). Measuring
regional perfusion with arterial spin labelling, Claassen et al. (2017)
found additional support for a hypersensitive mesocorticolimbic loop in
patients with ICD. Compared to patients without ICD, the administration
of dopamine agonists increased regional blood ﬂow in ventral striatum,
in proportion to ICD severity.
Lower D2/D3 receptor density in the ventral striatum correlates with
ICD severity (Payer et al., 2015), which at ﬁrst sight contradicts the
overdosing hypothesis, but might reﬂect a compensatory response. Other
ligand-based imaging studies have investigated task-related changes in
dynamic dopamine receptor binding, showing a relatively increased
dopamine release in ICD patients in the ventral striatum during gambling
tasks or the presentation of reward-cues (O’Sullivan et al., 2011; Steeves
et al., 2009) as well as diminished negative feedback control over
dopamine release in the midbrain (Ray et al., 2012).
A few imaging studies studied PD patients with and without ICD, both
ON and OFF dopaminergic medication, so as to test the hyper-sensitive
ventral striatal dopamine system and its reactivity to dopaminergic
medication. Voon and colleagues (Voon et al., 2011, 2010) acquired fMRI
data while patients learned stimulus-outcome probabilities in three
different conditions (loss vs. no loss, win vs. no win and neutral) or took
low- or high-risk decisions in a loss- or a gain-context. These studies
revealed complex effects of ICD pathology and dopaminergic medication
state on brain activity related to different aspects of the tasks. For
example, in the gain condition, ICD patients showed a stronger
medication-induced increase in ventral, but also posterior dorsal striatal
activity to positive prediction errors and gain prediction. Another key
ﬁnding was that ICD patients showed a reduced striatal signal to reward
omission, independent of medication (Voon et al., 2010), accompanied
by a stronger medication-induced increase in learning rate. Also in the
loss context, dopamine medication seemed to increase ventral and
anterior striatal responsivity to the omission of loss events while
decreasing the activity related to loss itself in ICD patients, again in line
with the idea that increased dopaminergic tone in striatal regions impairs
D2 mediated encoding of negative prediction errors (dips in DA) and D1
mediated positive prediction error signalling (phasic bursts) (Voon et al.,
2010).
ICD patients display reduced ventral striatal response to risk while ON
medication (Voon et al., 2011). This ﬁnding is at variance with the simple
expectation of higher signal with higher DA levels, but it might be related
to the problematic behaviour (e.g. gambling). ICD patients with hyper-
sexual disorder displayed stronger activity to sexual cues in the ventral
striatum, independently of medication state (Politis et al., 2013).
Together, these results suggest that increased dopaminergic activity
in ventral striatal regions, possibly accompanied by decreased dopa-
minergic activity in the PFC (van Eimeren et al., 2009), may underlie
the adverse effects of dopaminergic treatment on cognition and
behaviour in ICD. Averbeck et al. (2013) have suggested that this pa-
thology leads to an increased uncertainty about the utility of future
actions, which is underlying many aspects of ICD behaviour, such as
increased temporal discounting, reduced information sampling or
increased novelty seeking.
Most neuroimaging studies accord with the hypothesis of an exag-
gerated “overdosing” response in ventral striatum in PD-ICD patients. In
healthy individuals, there is an optimal balance of ventral striatal and
prefrontal tonic and phasic DA release, securing an optimal striatal-
prefrontal interplay when encoding the outcomes of actions as well as
when planning future actions. PD causes an imbalance in this complex
system which is further accentuated in patients with ICD by putative
susceptibility traits as well as dopaminergic medication. Neuroimaging
of PD patients with ICD provides additional insights into the function of
the dopaminergic system in cognition and especially reward related
D. Meder et al. NeuroImage 190 (2019) 79–93decisions. Future studies should take into account ICD subtypes, since
different forms of ICD are related to distinct behavioural and neurobio-
logical changes (Voon et al., 2017).
4. Discussion
The prominent nigrostriatal dopaminergic degeneration and routine
dopaminergic medication make PD a valuable “disease model” to probe
the functions of dopaminergic neurotransmission. Comparing the un-
medicated state (dopamine depletion) with the medicated state (restored
dopamine levels) allows inferences on the dopaminergic system's func-
tion in the healthy brain. Yet, there are many complexities of the disease
that prevent a simple interpretation of functional changes in brain ac-
tivity depending on the state of medication.
Nevertheless, key insights about the dopaminergic system in the
healthy brain emerge. Firstly, changes in dopamine levels not only affect
the striatum as a target area of dopaminergic neurons, but also cortical
areas show consistent activation changes. Studies on bradykinetic PD
patients suggest a crucial role for dopaminergic transmission in a cortico-
subcortical network centred on SMA, M1 and putamen for the enforce-
ment of movement vigour. In this same network, with additional
involvement of areas related to inhibitory action control (preSMA and
rIFG), dopamine dynamics also seem to be implicated in the development
of involuntary, purposeless movements, while the exact contribution of
prefrontal-basal ganglia networks to these involuntary movements re-
mains to be elucidated.
Studies on cognitive ﬂexibility indicate that the pattern of brain
activity changes due to disease and dopamine medication depend on (i)
the speciﬁc aspect of cognitive ﬂexibility under investigation and (ii)
type of task used in the experiment. Dopamine modulates many cortical
and subcortical areas, including the anterior dorsal striatum. The di-
versity of activity changes, both regarding the anatomical location and
the direction of the effects (activation and de-activation) point to the
existence of different optima of dopamine levels for different kinds of
cognitive tasks in different neural networks. The amount of neuro-
degeneration differs among ventral and dorsal nigrostriatal pathways,
causing different magnitudes of dopamine depletion. This explains why
dopamine replacement therapy results in restoration or overdosing of
dopamine levels in dorsal and ventral striatal territories, leading to
functional improvement or deterioration by moving towards or away
from this optimal level along an inverse U-shaped curve. This interac-
tion is additionally modulated by individual COMT variants, affecting
prefrontal dopamine levels (Collins and Williams-Gray, 2016; Nombela
et al., 2014b). Studies using noradrenergic manipulation in tasks on
inhibitory control reveal that other neurotransmitters may be equally
affected by neurodegeneration and point to an important role of
noradrenalin for the response inhibition network with the right IFG as
core node.
In addition, experiments on reward, punishment and learning clearly
show a strong inﬂuence of dopamine on these aspects of cognition. These
results can be difﬁcult to interpret in the absence of sufﬁciently precise
predictions about how changes in tonic dopamine levels due to nigros-
triatal neurodegeneration and dopamine replacement therapy affect
phasic ﬁring patterns of dopaminergic neurons; and how this in turn
affects receptor-speciﬁc striatal responses to dopamine release. The
relatively spared VTA-ventral striatum pathways are overdosed by
dopaminergic treatment, moving subjects away from optimal perfor-
mance, especially in those with ICDs.
We do not propose a simplistic uniﬁed theory of dopamine function in
the brain. There is evidence for the role of dopamine for adequate
movement generation and reward prediction error processing, and in
cognitive ﬂexibility, but via different functional anatomical systems with
differences in their optimal dopamine levels. In PD, there is no general-
ised optimal level of dopaminergic medication to meet all systems.
Rather, different dopaminergic states optimise brain networks for motor
and cognitive performance.894.1. Moving forward
What are the lessons to be learned from existing functional neuro-
imaging studies that can guide the design of future fMRI studies in PD
patients? First, a sufﬁcient sample size is of paramount importance
despite the practical difﬁculties of recruitment and study adherence in
studies with multiple test days. The low sample sizes in many early
studies, including some of those reviewed here, most likely accounts for
most of the variability of results across studies, resulting in low power
and reproducibility (Button et al., 2013). Second, to enable a better
mechanistic interpretation, there is a clear need for well-designed ex-
periments in which patients are tested both OFF and ON medication and
preferably also compared against healthy controls to dissect different
aspects of cognition, action selection and motor behaviour. Third, the
cognitive process under investigation needs to be isolated from con-
founding variables, either via the experimental design (cognitive sub-
traction, but see e.g. Friston et al. (1996)) or by applying computational
models that allow the investigation of otherwise hidden latent variables.
Tracking the change in parameter values by medication or disease state
can give deep insights into computational changes underlying a number
of disease and medication related symptoms (Huys et al., 2016). Also,
multivariate analysis approaches are highly sensitive methods that can
provide insights that classical univariate analyses are unable to reveal
(Lessov-Schlaggar et al., 2016).
Furthermore, future neuroimaging research should take into account
the involvement of other neurotransmitters because neurodegeneration
extends beyond the dopaminergic system. These include noradrenalin,
serotonin and acetylcholine, and their effects both individually and in
conjunction with dopamine.
Fourth, a better understanding of compensatory effects and the dy-
namics of dopaminergic medication is needed. Some studies ﬁnd
increased activation or connectivity in PD patients OFF medication,
which could be interpreted as compensatory mechanisms or a loss of
efﬁciency (e.g. Cerasa et al., 2015b; Mallol et al., 2007; Poston et al.,
2016; Turner et al., 2003). Few studies use dopamine medication in
drug-naïve patients, but this cannot be assumed to be equivalent to acute
drug-withdrawal regimes in patients with long-term medical treatment
(Navntoft and Dreyer, 2016; Payer et al., 2015). For example, one study
compared non-medicated early PD patients just before treatment against
the same patients after 12 weeks and against recently medicated PD
patients, showing differential effects on learning from punishment or
reward (Bodi et al., 2009). Another example for the importance of un-
derstanding longer-term dynamics of disease progression comes from
studies suggesting a compensatory upregulation of prefrontal dopamine
metabolism in early, but not late PD patients (Kaasinen et al., 2001;
Rakshi et al., 1999).
Fifth, we would like to point out that functional neuroimaging of
resting-state connectivity has identiﬁed a unique PD-related pattern of
changes in pallidum, thalamus and premotor regions associated with
motor symptoms as well as a PD-related cognitive pattern in medial
prefrontal, parietal associative and cerebellar regions associated with
cognitive dysfunction (Eidelberg, 2009; Tahmasian et al., 2015). The
changes in resting-state connectivity related to PD and medication state
involve brain regions outside the cortico-striatal pathways. This warrants
an extended perspective on candidate regions (e.g. cerebellum or hip-
pocampus) for future investigation (Tahmasian et al., 2015). Finally,
there is a clear need for a better understanding of the effects of tonic
dopamine level manipulations on the phasic ﬁring patterns which are at
the core of reinforcement learning, highlighting the importance of ani-
mal studies that allow for causal manipulations and measures of activity
and transmitter concentrations with high spatial and temporal resolu-
tion. Valuable contributions to these efforts can also be expected from
ultra high-ﬁeld MR, allowing a more precise characterization of the in-
dividual degree of neurodegeneration in different brain nuclei and
relating this to changes in activity depending on the state of medication
and in comparison with healthy subjects (Lehericy et al., 2017).
D. Meder et al. NeuroImage 190 (2019) 79–93Conﬂicts of interest
Hartwig R. Siebner has received honoraria as speaker from Sanoﬁ
Genzyme, Denmark and as senior editor of NeuroImage from Elsevier
Publishers, Amsterdam, The Netherlands and Springer Publishing,
Stuttgart, Germany, and has received a research fund from Biogen-idec.
James Rowe serves as Editor for Brain, and the Scientiﬁc Advisory
Board for Asceneuron, with research grants from AZ-Medimmune unre-
lated to this work. The remaining authors have no conﬂicts of interest.
Acknowledgements
This work was supported by a project grant of the NovoNordisk
Foundation [grant number NNF16OC0023090]. JBR is supported by the
Wellcome Trust (103838). HRS holds a full professorship in precision
medicine at the Faculty of Health and Medical Sciences, University of
Copenhagen, sponsored by the Lundbeck Foundation.
References
Aarts, E., Helmich, R.C., Janssen, M.J.R., Oyen, W.J.G., Bloem, B.R., Cools, R., 2012.
Aberrant reward processing in Parkinson's disease is associated with dopamine cell
loss. NeuroImage 59, 3339–3346. https://doi.org/10.1016/j.neuroimage.2011.11.
073.
Aarts, E., Nusselein, A.A.M., Smittenaar, P., Helmich, R.C., Bloem, B.R., Cools, R., 2014.
Greater striatal responses to medication in Parkinson׳s disease are associated with
better task-switching but worse reward performance. Neuropsychologia 62, 390–397.
https://doi.org/10.1016/j.neuropsychologia.2014.05.023.
Ahlskog, J.E., Muenter, M.D., 2001. Frequency of levodopa-related dyskinesias and motor
ﬂuctuations as estimated from the cumulative literature. Mov. Disord. Off. J. Mov.
Disord. Soc. 16, 448–458.
Alberico, S.L., Cassell, M.D., Narayanan, N.S., 2015. The vulnerable ventral tegmental
area in Parkinson's disease. Basal Ganglia 5, 51–55. https://doi.org/10.1016/j.baga.
2015.06.001.
Arnsten, A.F.T., Cai, J.X., Murphy, B.L., Goldman-Rakic, P.S., 1994. Dopamine D1
receptor mechanisms in the cognitive performance of young adult and aged monkeys.
Psychopharmacology (Berlin) 116, 143–151. https://doi.org/10.1007/BF02245056.
Aron, A.R., Obeso, J., 2012. Is executive control used to compensate for involuntary
movements in levodopa-induced dyskinesia? Mov. Disord. 27, 339–340. https://doi.
org/10.1002/mds.24936.
Aron, A.R., Herz, D.M., Brown, P., Forstmann, B.U., Zaghloul, K., 2016.
Frontosubthalamic circuits for control of action and cognition. J. Neurosci. 36,
11489–11495. https://doi.org/10.1523/JNEUROSCI.2348-16.2016.
Averbeck, B.B., Djamshidian, A., O'Sullivan, S.S., Housden, C.R., Roiser, J.P., Lees, A.J.,
2013. Uncertainty about mapping future actions into rewards may underlie
performance on multiple measures of impulsivity in behavioral addiction: evidence
from Parkinson's disease. Behav. Neurosci. 127, 245–255. https://doi.org/10.1037/
a0032079.
Baraduc, P., Thobois, S., Gan, J., Broussolle, E., Desmurget, M., 2013. A common
optimization principle for motor execution in healthy subjects and parkinsonian
patients. J. Neurosci. 33, 665–677. https://doi.org/10.1523/JNEUROSCI.1482-12.
2013.
Behrens, T.E.J., Woolrich, M., Walton, M.E., Rushworth, M.F.S., 2007. Learning the value
of information in an uncertain world. Nat. Neurosci. 10, 1214–1221.
Beierholm, U., Guitart-Masip, M., Economides, M., Chowdhury, R., Düzel, E., Dolan, R.,
Dayan, P., 2013. Dopamine modulates reward-related vigor.
Neuropsychopharmacology 38, 1495–1503. https://doi.org/10.1038/npp.2013.48.
Berardelli, A., Rothwell, J.C., Thompson, P.D., Hallett, M., 2001. Pathophysiology of
bradykinesia in Parkinson's disease. Brain 124, 2131–2146. https://doi.org/10.
1093/brain/124.11.2131.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F., 1973.
Brain dopamine and the syndromes of Parkinson and Huntington Clinical,
morphological and neurochemical correlations. J. Neurol. Sci. 20, 415–455. https://
doi.org/10.1016/0022-510X(73)90175-5.
Bethus, I., Tse, D., Morris, R.G.M., 2010. Dopamine and memory: modulation of the
persistence of memory for novel hippocampal NMDA receptor-dependent paired
associates. J. Neurosci. 30, 1610–1618. https://doi.org/10.1523/JNEUROSCI.2721-
09.2010.
Birkmayer, W., Hornykiewicz, O., 1961. The effect of l-3,4-dihydroxyphenylalanine
(¼DOPA) on akinesia in parkinsonism. Wien Klin. Wochenschr. 73, 787–788.
Bodi, N., Keri, S., Nagy, H., Moustafa, A., Myers, C.E., Daw, N., Dibo, G., Takats, A.,
Bereczki, D., Gluck, M.A., 2009. Reward-learning and the novelty-seeking
personality: a between- and within-subjects study of the effects of dopamine agonists
on young Parkinson's patients. Brain 132, 2385–2395. https://doi.org/10.1093/
brain/awp094.
Borchert, R.J., Rittman, T., Passamonti, L., Ye, Z., Sami, S., Jones, S.P., Nombela, C.,
Vazquez Rodríguez, P., Vatansever, D., Rae, C.L., Hughes, L.E., Robbins, T.W.,
Rowe, J.B., 2016. Atomoxetine enhances connectivity of prefrontal networks in
Parkinson's disease. Neuropsychopharmacology 41, 2171–2177. https://doi.org/10.
1038/npp.2016.18.90Bouc, R.L., Rigoux, L., Schmidt, L., Degos, B., Welter, M.-L., Vidailhet, M., Daunizeau, J.,
Pessiglione, M., 2016. Computational dissection of dopamine motor and motivational
functions in humans. J. Neurosci. 36, 6623–6633. https://doi.org/10.1523/
JNEUROSCI.3078-15.2016.
Braak, H., Tredici, K.D., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, E., 2003.
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging
24, 197–211. https://doi.org/10.1016/S0197-4580(02)00065-9.
Brooks, D.J., Piccini, P., Turjanski, N., Samuel, M., 2000. Neuroimaging of dyskinesia.
Ann. Neurol. 47, S154–S158 discussion S158-9.
Brusa, L., Versace, V., Koch, G., Iani, C., Stanzione, P., Bernardi, G., Centonze, D., 2006.
Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's
disease. Clin. Neurophysiol. 117, 1917–1921. https://doi.org/10.1016/j.clinph.
2006.03.033.
Buhmann, C., Glauche, V., Stürenburg, H.J., Oechsner, M., Weiller, C., Büchel, C., 2003.
Pharmacologically modulated fMRI—cortical responsiveness to levodopa in drug-
naive hemiparkinsonian patients. Brain 126, 451–461. https://doi.org/10.1093/
brain/awg033.
Button, K.S., Ioannidis, J.P.A., Mokrysz, C., Nosek, B.A., Flint, J., Robinson, E.S.J.,
Munafo, M.R., 2013. Power failure: why small sample size undermines the reliability
of neuroscience. Nat. Rev. Neurosci. 14, 365–376. https://doi.org/10.1038/nrn3475.
Calabresi, P., Saiardi, A., Pisani, A., Baik, J.-H., Centonze, D., Mercuri, N.B., Bernardi, G.,
Borrelli, E., 1997. Abnormal synaptic plasticity in the striatum of mice lacking
dopamine D2 receptors. J. Neurosci. 17, 4536–4544.
Cenci, M.A., Lundblad, M., 2006. Post- versus presynaptic plasticity in L-DOPA-induced
dyskinesia. J. Neurochem. 99, 381–392. https://doi.org/10.1111/j.1471-4159.2006.
04124.x.
Cerasa, A., Messina, D., Pugliese, P., Morelli, M., Lanza, P., Salsone, M., Novellino, F.,
Nicoletti, G., Arabia, G., Quattrone, A., 2011. Increased prefrontal volume in PD with
levodopa-induced dyskinesias: a voxel-based morphometry study. Mov. Disord. 26,
807–812. https://doi.org/10.1002/mds.23660.
Cerasa, A., Pugliese, P., Messina, D., Morelli, M., Cecilia Gioia, M., Salsone, M.,
Novellino, F., Nicoletti, G., Arabia, G., Quattrone, A., 2012. Prefrontal alterations in
Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov.
Disord. 27, 364–371. https://doi.org/10.1002/mds.24017.
Cerasa, A., Donzuso, G., Morelli, M., Mangone, G., Salsone, M., Passamonti, L.,
Augimeri, A., Arabia, G., Quattrone, A., 2015a. The motor inhibition system in
Parkinson's disease with levodopa-induced dyskinesias. Mov. Disord. 30, 1912–1920.
https://doi.org/10.1002/mds.26378.
Cerasa, A., Koch, G., Donzuso, G., Mangone, G., Morelli, M., Brusa, L., Stampanoni
Bassi, M., Ponzo, V., Picazio, S., Passamonti, L., Salsone, M., Augimeri, A.,
Caltagirone, C., Quattrone, A., 2015b. A network centred on the inferior frontal
cortex is critically involved in levodopa-induced dyskinesias. Brain 138, 414–427.
https://doi.org/10.1093/brain/awu329.
Cerasa, A., Koch, G., Fasano, A., Morgante, F., 2015c. Future scenarios for levodopa-
induced dyskinesias in Parkinson's disease. Front. Neurol. 6. https://doi.org/10.
3389/fneur.2015.00076.
Chong, T.T.-J., Bonnelle, V., Manohar, S., Veromann, K.-R., Muhammed, K., Tofaris, G.K.,
Hu, M., Husain, M., 2015. Dopamine enhances willingness to exert effort for reward
in Parkinson's disease. Cortex 69, 40–46. https://doi.org/10.1016/j.cortex.2015.04.
003.
Christopoulos, G.I., Tobler, P.N., Bossaerts, P., Dolan, R.J., Schultz, W., 2009. Neural
correlates of value, risk, and risk aversion contributing to decision making under risk.
J. Neurosci. 29, 12574–12583. https://doi.org/10.1523/JNEUROSCI.2614-09.2009.
Cilia, R., van Eimeren, T., 2011. Impulse control disorders in Parkinson's disease: seeking
a roadmap toward a better understanding. Brain Struct. Funct. 216, 289–299.
https://doi.org/10.1007/s00429-011-0314-0.
Cilia, R., Ko, J.H., Cho, S.S., van Eimeren, T., Marotta, G., Pellecchia, G., Pezzoli, G.,
Antonini, A., Strafella, A.P., 2010. Reduced dopamine transporter density in the
ventral striatum of patients with Parkinson's disease and pathological gambling.
Neurobiol. Dis., Epigenetics and Neuropsychiatric Disease 39, 98–104. https://doi.
org/10.1016/j.nbd.2010.03.013.
Cilia, R., Akpalu, A., Sarfo, F.S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P.,
Akassi, J., Bonetti, A., Pezzoli, G., 2014. The modern pre-levodopa era of Parkinson's
disease: insights into motor complications from sub-Saharan Africa. Brain 137,
2731–2742. https://doi.org/10.1093/brain/awu195.
Claassen, D.O., Stark, A.J., Spears, C.A., Petersen, K.J., Wouwe, van, Kessler, R.M.,
Zald, D.H., Donahue, M.J., 2017. Mesocorticolimbic hemodynamic response in
Parkinson's disease patients with compulsive behaviors. Mov. Disord. 32, 1574–1583.
https://doi.org/10.1002/mds.27047.
Collins, A.G.E., Frank, M.J., 2014. Opponent actor learning (OpAL): modeling interactive
effects of striatal dopamine on reinforcement learning and choice incentive. Psychol.
Rev. 121, 337–366. July 2014. https://doi.org/10.1037/a0037015.
Collins, L.M., Williams-Gray, C.H., 2016. The genetic basis of cognitive impairment and
dementia in Parkinson's disease. Front. Psychiatr. 7. https://doi.org/10.3389/fpsyt.
2016.00089.
Cools, R., 2006. Dopaminergic modulation of cognitive function-implications for l-DOPA
treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 30, 1–23. https://doi.org/
10.1016/j.neubiorev.2005.03.024.
Cools, R., Barker, R.A., Sahakian, B.J., Robbins, T.W., 2001. Enhanced or impaired
cognitive function in Parkinson's disease as a function of dopaminergic medication
and task demands. Cerebr. Cortex 11, 1136–1143. https://doi.org/10.1093/cercor/
11.12.1136.
Cools, R., Lewis, S.J.G., Clark, L., Barker, R.A., Robbins, T.W., 2007. L-DOPA disrupts
activity in the nucleus accumbens during reversal learning in Parkinson's disease.
Neuropsychopharmacology 32, 180–189.
D. Meder et al. NeuroImage 190 (2019) 79–93Cotzias, G.C., Papavasiliou, P.S., Gellene, R., 1969. Serum renin levels and
postnephrectomy blood pressure. N. Engl. J. Med. 281, 272–273. https://doi.org/10.
1056/NEJM196907312810518.
Coulthard, E.J., Bogacz, R., Javed, S., Mooney, L.K., Murphy, G., Keeley, S., Whone, A.L.,
2012. Distinct roles of dopamine and subthalamic nucleus in learning and
probabilistic decision making. Brain 135, 3721–3734. https://doi.org/10.1093/
brain/aws273.
Dudman, J.T., Krakauer, J.W., 2016. The basal ganglia: from motor commands to the
control of vigor. Curr. Opin. Neurobiol., Neurobiology of cognitive behavior 37,
158–166. https://doi.org/10.1016/j.conb.2016.02.005.
Edwards, M., Bhatia, K., Quinn, N.P., 2008. Parkinson's Disease and Other Movement
Disorders, Oxford Specialist Handbooks in Neurology. Oxford University Press,
Oxford.
Eidelberg, D., 2009. Metabolic brain networks in neurodegenerative disorders: a
functional imaging approach. Trends Neurosci. 32, 548–557. https://doi.org/10.
1016/j.tins.2009.06.003.
Esposito, F., Tessitore, A., Giordano, A., De Micco, R., Paccone, A., Conforti, R.,
Pignataro, G., Annunziato, L., Tedeschi, G., 2013. Rhythm-speciﬁc modulation of the
sensorimotor network in drug-naïve patients with Parkinson's disease by levodopa.
Brain 136, 710–725. https://doi.org/10.1093/brain/awt007.
Fallon, S.J., Williams-Gray, C.H., Barker, R.A., Owen, A.M., Hampshire, A., 2013.
Prefrontal dopamine levels determine the balance between cognitive stability and
ﬂexibility. Cerebr. Cortex 23, 361–369. https://doi.org/10.1093/cercor/bhs025.
Fearnley, J.M., Lees, A.J., 1991. Ageing and Parkinson's disease: substantia nigra regional
selectivity. Brain 114, 2283–2301. https://doi.org/10.1093/brain/114.5.2283.
Fiore, V.G., Nolte, T., Rigoli, F., Smittenaar, P., Gu, X., Dolan, R.J., 2018. Value encoding
in the globus pallidus: fMRI reveals an interaction effect between reward and
dopamine drive. NeuroImage 173, 249–257. https://doi.org/10.1016/j.neuroimage.
2018.02.048.
Frank, M.J., Seeberger, L.C., O'Reilly, R.C., 2004. By carrot or by stick: cognitive
reinforcement learning in parkinsonism. Science 306, 1940–1943. https://doi.org/
10.1126/science.1102941.
Friston, K.J., Price, C.J., Fletcher, P., Moore, C., Frackowiak, R.S.J., Dolan, R.J., 1996. The
trouble with cognitive subtraction. NeuroImage 4, 97–104. https://doi.org/10.1006/
nimg.1996.0033.
Gratwicke, J.P., Foltynie, T., 2018. Early nucleus basalis of Meynert degeneration predicts
cognitive decline in Parkinson's disease. Brain 141, 7–10. https://doi.org/10.1093/
brain/awx333.
Gratwicke, J., Jahanshahi, M., Foltynie, T., 2015. Parkinson's disease dementia: a neural
networks perspective. Brain 138, 1454–1476. https://doi.org/10.1093/brain/
awv104.
Grogan, J.P., Tsivos, D., Smith, L., Knight, B.E., Bogacz, R., Whone, A., Coulthard, E.J.,
2017. Effects of dopamine on reinforcement learning and consolidation in Parkinson's
disease. eLife 6 e26801. https://doi.org/10.7554/eLife.26801.
Haber, S.N., 2003. The primate basal ganglia: parallel and integrative networks. J. Chem.
Neuroanat. 26, 317–330. Special Issue on the Human Brain - The Structural Basis for
understanding Human Brain function and dysfunction. https://doi.org/10.1016/j.
jchemneu.2003.10.003.
Hallett, M., Khoshbin, S., 1980. A physiological mechanism of bradykinesia. Brain 103,
301–314. https://doi.org/10.1093/brain/103.2.301.
Hauser, R.A., 2009. Levodopa: past, present, and future. Eur. Neurol. 62, 1–8. https://doi.
org/10.1159/000215875.
Hawkes, C.H., Del Tredici, K., Braak, H., 2010. A timeline for Parkinson's disease. Park.
Relat. Disord. 16, 79–84. https://doi.org/10.1016/j.parkreldis.2009.08.007.
Herz, D.M., Christensen, M.S., Bruggemann, N., Hulme, O.J., Ridderinkhof, K.R.,
Madsen, K.H., Siebner, H.R., 2014a. Motivational tuning of fronto-subthalamic
connectivity facilitates control of action impulses. J. Neurosci. 34, 3210–3217.
https://doi.org/10.1523/JNEUROSCI.4081-13.2014.
Herz, D.M., Eickhoff, S.B., Løkkegaard, A., Siebner, H.R., 2014b. Functional neuroimaging
of motor control in Parkinson's disease: a meta-analysis. Hum. Brain Mapp. 35,
3227–3237. https://doi.org/10.1002/hbm.22397.
Herz, D.M., Haagensen, B.N., Christensen, M.S., Madsen, K.H., Rowe, J.B., Løkkegaard, A.,
Siebner, H.R., 2014c. The acute brain response to levodopa heralds dyskinesias in
Parkinson disease. Ann. Neurol. 75, 829–836. https://doi.org/10.1002/ana.24138.
Herz, D.M., Haagensen, B.N., Christensen, M.S., Madsen, K.H., Rowe, J.B., Løkkegaard, A.,
Siebner, H.R., 2015. Abnormal dopaminergic modulation of striato-cortical networks
underlies levodopa-induced dyskinesias in humans. Brain 138, 1658–1666. https://
doi.org/10.1093/brain/awv096.
Herz, D.M., Haagensen, B.N., Nielsen, S.H., Madsen, K.H., Løkkegaard, A., Siebner, H.R.,
2016. Resting-state connectivity predicts levodopa-induced dyskinesias in
Parkinson's disease. Mov. Disord. 31, 521–529. https://doi.org/10.1002/mds.26540.
Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., 1992. Accuracy of clinical diagnosis of
idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol.
Neurosurg. Psychiatry 55, 181–184. https://doi.org/10.1136/jnnp.55.3.181.
Hughes, L.E., Barker, R.A., Owen, A.M., Rowe, J.B., 2010. Parkinson's disease and healthy
aging: independent and interacting effects on action selection. Hum. Brain Mapp. 31,
1886–1899. https://doi.org/10.1002/hbm.20979.
Hughes, L.E., Altena, E., Barker, R.A., Rowe, J.B., 2013. Perseveration and choice in
Parkinson's disease: the impact of progressive frontostriatal dysfunction on action
decisions. Cerebr. Cortex 23, 1572–1581. https://doi.org/10.1093/cercor/bhs144.
Huys, Q.J.M., Maia, T.V., Frank, M.J., 2016. Computational psychiatry as a bridge from
neuroscience to clinical applications. Nat. Neurosci. 19, 404–413. https://doi.org/10.
1038/nn.4238.
Ingvarsson, P.E., Gordon, A.M., Forssberg, H., 1997. Coordination of manipulative forces
in Parkinson's disease. Exp. Neurol. 145, 489–501. https://doi.org/10.1006/exnr.
1997.6480.91Jellinger, K.A., 1999. Post mortem studies in Parkinson's disease–is it possible to detect
brain areas for speciﬁc symptoms? J. Neural. Transm. Suppl. 56, 1–29.
Johansen-Berg, H., Behrens, T.E.J., Robson, M.D., Drobnjak, I., Rushworth, M.F.S.,
Brady, J.M., Smith, S.M., Higham, D.J., Matthews, P.M., 2004. Changes in
connectivity proﬁles deﬁne functionally distinct regions in human medial frontal
cortex. Proc. Natl. Acad. Sci. Unit. States Am. 101, 13335–13340. https://doi.org/10.
1073/pnas.0403743101.
Kaasinen, V., Nurmi, E., Brück, A., Eskola, O., Bergman, J., Solin, O., Rinne, J.O., 2001.
Increased frontal [18F]ﬂuorodopa uptake in early Parkinson's disease: sex differences
in the prefrontal cortex. Brain 124, 1125–1130. https://doi.org/10.1093/brain/124.
6.1125.
Kalia, L.V., Lang, A.E., 2015. Parkinson's disease. Lancet 386, 896–912. https://doi.org/
10.1016/S0140-6736(14)61393-3.
Kehagia, A.A., Barker, R.A., Robbins, T.W., 2013. Cognitive impairment in Parkinson's
disease: the dual syndrome hypothesis. Neurodegener. Dis. 11, 79–92. https://doi.
org/10.1159/000341998.
Kim, J., Criaud, M., Cho, S.S., Díez-Cirarda, M., Mihaescu, A., Coakeley, S., Ghadery, C.,
Valli, M., Jacobs, M.F., Houle, S., Strafella, A.P., 2017. Abnormal intrinsic brain
functional network dynamics in Parkinson's disease. Brain 140, 2955–2967. https://
doi.org/10.1093/brain/awx233.
Kish, S.J., Shannak, K., Hornykiewicz, O., 1988. Uneven pattern of dopamine loss in the
striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318,
876–880. https://doi.org/10.1056/NEJM198804073181402.
Koch, G., Brusa, L., Caltagirone, C., Peppe, A., Oliveri, M., Stanzione, P., Centonze, D.,
2005. rTMS of supplementary motor area modulates therapy-induced dyskinesias in
Parkinson disease. Neurology 65, 623–625. https://doi.org/10.1212/01.wnl.
0000172861.36430.95.
Kraft, E., Loichinger, W., Diepers, M., Lule, D., Schwarz, J., Ludolph, A.C., Storch, A.,
2009. Levodopa-induced striatal activation in Parkinson's disease: a functional MRI
study. Park. Relat. Disord. 15, 558–563. https://doi.org/10.1016/j.parkreldis.2009.
02.005.
Krakauer, J.W., Ghazanfar, A.A., Gomez-Marin, A., MacIver, M.A., Poeppel, D., 2017.
Neuroscience needs behavior: correcting a reductionist bias. Neuron 93, 480–490.
https://doi.org/10.1016/j.neuron.2016.12.041.
Le Heron, C., Plant, O., Manohar, S., Ang, Y.-S., Jackson, M., Lennox, G., Hu, M.T.,
Husain, M., 2018. Distinct effects of apathy and dopamine on effort-based decision-
making in Parkinson's disease. Brain 141, 1455–1469. https://doi.org/10.1093/
brain/awy110.
Lehericy, S., Vaillancourt, D.E., Seppi, K., Monchi, O., Rektorova, I., Antonini, A.,
McKeown, M.J., Masellis, M., Berg, D., Rowe, J.B., Lewis, S.J.G., Williams-Gray, C.H.,
Tessitore, A., Siebner, H.R., On behalf of the International Parkinson and Movement
Disorder Society (IPMDS)-Neuroimaging Study Group, 2017. The role of high-ﬁeld
magnetic resonance imaging in parkinsonian disorders: pushing the boundaries
forward. Mov. Disord. 32, 510–525. https://doi.org/10.1002/mds.26968.
Lessov-Schlaggar, C.N., Rubin, J.B., Schlaggar, B.L., 2016. The fallacy of univariate
solutions to complex systems problems. Front. Neurosci. 10. https://doi.org/10.
3389/fnins.2016.00267.
MacDonald, P.A., MacDonald, A.A., Seergobin, K.N., Tamjeedi, R., Ganjavi, H.,
Provost, J.-S., Monchi, O., 2011. The effect of dopamine therapy on ventral and
dorsal striatum-mediated cognition in Parkinson's disease: support from functional
MRI. Brain 134, 1447–1463. https://doi.org/10.1093/brain/awr075.
Mallol, R., Barros-Loscertales, A., Lopez, M., Belloch, V., Parcet, M.A., Avila, C., 2007.
Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI
during the performance of pre-learned sequential movements. Brain Res. 1147,
265–271. https://doi.org/10.1016/j.brainres.2007.02.046.
Maril, S., Hassin-Baer, S., Cohen, O.S., Tomer, R., 2013. Effects of asymmetric dopamine
depletion on sensitivity to rewarding and aversive stimuli in Parkinson's disease.
Neuropsychologia 51, 818–824. https://doi.org/10.1016/j.neuropsychologia.2013.
02.003.
Massano, J., Bhatia, K.P., 2012. Clinical approach to Parkinson's disease: features,
diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2
a008870. https://doi.org/10.1101/cshperspect.a008870.
Mazzoni, P., Hristova, A., Krakauer, J.W., 2007. Why don't we move faster? Parkinson's
disease, movement vigor, and implicit motivation. J. Neurosci. 27, 7105–7116.
https://doi.org/10.1523/JNEUROSCI.0264-07.2007.
Meder, D., Kolling, N., Verhagen, L., Wittmann, M.K., Scholl, J., Madsen, K.H.,
Hulme, O.J., Behrens, T.E.J., Rushworth, M.F.S., 2017. Simultaneous representation
of a spectrum of dynamically changing value estimates during decision making. Nat.
Commun. 8, 1942. https://doi.org/10.1038/s41467-017-02169-w.
Muakkassa, K.F., Strick, P.L., 1979. Frontal lobe inputs to primate motor cortex: evidence
for four somatotopically organized ‘premotor’ areas. Brain Res. 177, 176–182.
https://doi.org/10.1016/0006-8993(79)90928-4.
Nachev, P., Kennard, C., Husain, M., 2008. Functional role of the supplementary and pre-
supplementary motor areas. Nat. Rev. Neurosci. 9, 856–869. https://doi.org/10.
1038/nrn2478.
Nassar, M.R., Wilson, R.C., Heasly, B., Gold, J.I., 2010. An approximately bayesian delta-
rule model explains the dynamics of belief updating in a changing environment.
J. Neurosci. 30, 12366–12378. https://doi.org/10.1523/JNEUROSCI.0822-10.2010.
Navntoft, C.A., Dreyer, J.K., 2016. How compensation breaks down in Parkinson's
disease: insights from modeling of denervated striatum. Mov. Disord. 31, 280–289.
https://doi.org/10.1002/mds.26579.
Niv, Y., Daw, N.D., Joel, D., Dayan, P., 2007. Tonic dopamine: opportunity costs and the
control of response vigor. Psychopharmacology (Berlin) 191, 507–520. https://doi.
org/10.1007/s00213-006-0502-4.
D. Meder et al. NeuroImage 190 (2019) 79–93Nombela, C., Rittman, T., Robbins, T.W., Rowe, J.B., 2014a. Multiple modes of
impulsivity in Parkinson's disease. PLOS ONE 9 e85747. https://doi.org/10.1371/
journal.pone.0085747.
Nombela, C., Rowe, J.B., Winder-Rhodes, S.E., Hampshire, A., Owen, A.M., Breen, D.P.,
Duncan, G.W., Khoo, T.K., Yarnall, A.J., Firbank, M.J., Chinnery, P.F., Robbins, T.W.,
O'Brien, J.T., Brooks, D.J., Burn, D.J., Barker, R.A., 2014b. Genetic impact on
cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD
study. Brain 137, 2743–2758. https://doi.org/10.1093/brain/awu201.
Nutt, J.G., 2008. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 23,
S580–S584. https://doi.org/10.1002/mds.22037.
Obeso, I., Strafella, A.P., 2014. Top-down control of dyskinesias in PD using brain
stimulation. Brain Stimulat 7, 488. https://doi.org/10.1016/j.brs.2014.01.005.
Obeso, I., Wilkinson, L., Jahanshahi, M., 2011. Levodopa medication does not inﬂuence
motor inhibition or conﬂict resolution in a conditional stop-signal task in Parkinson's
disease. Exp. Brain Res. 213, 435. https://doi.org/10.1007/s00221-011-2793-x.
O'Sullivan, S.S., Wu, K., Politis, M., Lawrence, A.D., Evans, A.H., Bose, S.K.,
Djamshidian, A., Lees, A.J., Piccini, P., 2011. Cue-induced striatal dopamine release
in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 134,
969–978. https://doi.org/10.1093/brain/awr003.
Palminteri, S., Lebreton, M., Worbe, Y., Grabli, D., Hartmann, A., Pessiglione, M., 2009.
Pharmacological modulation of subliminal learning in Parkinson's and Tourette's
syndromes. Proc. Natl. Acad. Sci. Unit. States Am. 106, 19179–19184. https://doi.
org/10.1073/pnas.0904035106.
Panigrahi, B., Martin, K.A., Li, Y., Graves, A.R., Vollmer, A., Olson, L., Mensh, B.D.,
Karpova, A.Y., Dudman, J.T., 2015. Dopamine is required for the neural
representation and control of movement vigor. Cell 162, 1418–1430. https://doi.
org/10.1016/j.cell.2015.08.014.
Payer, D.E., Guttman, M., Kish, S.J., Tong, J., Strafella, A., Zack, M., Adams, J.R.,
Rusjan, P., Houle, S., Furukawa, Y., Wilson, A.A., Boileau, I., 2015. [11C]-(þ)-PHNO
PET imaging of dopamine D2/3 receptors in Parkinson's disease with impulse control
disorders. Mov. Disord. 30, 160–166. https://doi.org/10.1002/mds.26135.
Picard, N., Strick, P.L., 2001. Imaging the premotor areas. Curr. Opin. Neurobiol. 11,
663–672. https://doi.org/10.1016/S0959-4388(01)00266-5.
Politis, M., Loane, C., Wu, K., O'Sullivan, S.S., Woodhead, Z., Kiferle, L., Lawrence, A.D.,
Lees, A.J., Piccini, P., 2013. Neural response to visual sexual cues in dopamine
treatment-linked hypersexuality in Parkinson's disease. Brain 136, 400–411. https://
doi.org/10.1093/brain/aws326.
Poston, K.L., YorkWilliams, S., Zhang, K., Cai, W., Everling, D., Tayim, F.M., Llanes, S.,
Menon, V., 2016. Compensatory neural mechanisms in cognitively unimpaired
Parkinson disease. Ann. Neurol. 79, 448–463. https://doi.org/10.1002/ana.24585.
Rae, C.L., Hughes, L.E., Weaver, C., Anderson, M.C., Rowe, J.B., 2014. Selection and
stopping in voluntary action: a meta-analysis and combined fMRI study. NeuroImage
86, 381–391. https://doi.org/10.1016/j.neuroimage.2013.10.012.
Rae, C.L., Nombela, C., Rodríguez, P.V., Ye, Z., Hughes, L.E., Jones, P.S., Ham, T.,
Rittman, T., Coyle-Gilchrist, I., Regenthal, R., Sahakian, B.J., Barker, R.A.,
Robbins, T.W., Rowe, J.B., 2016. Atomoxetine restores the response inhibition
network in Parkinson's disease. Brain 139, 2235–2248. https://doi.org/10.1093/
brain/aww138.
Rakshi, J.S., Uema, T., Ito, K., Bailey, D.L., Morrish, P.K., Ashburner, J., Dagher, A.,
Jenkins, I.H., Friston, K.J., Brooks, D.J., 1999. Frontal, midbrain and striatal
dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-
PET study. Brain 122, 1637–1650. https://doi.org/10.1093/brain/122.9.1637.
Rascol, O., Sabatini, U., Brefel, C., Fabre, N., Rai, S., Senard, J.M., Celsis, P., Viallard, G.,
Montastruc, J.L., Chollet, F., 1998. Cortical motor overactivation in parkinsonian
patients with L-dopa-induced peak-dose dyskinesia. Brain 121, 527–533. https://doi.
org/10.1093/brain/121.3.527.
Ray, N.J., Miyasaki, J.M., Zurowski, M., Ko, J.H., Cho, S.S., Pellecchia, G., Antonelli, F.,
Houle, S., Lang, A.E., Strafella, A.P., 2012. Extrastriatal dopaminergic abnormalities
of DA homeostasis in Parkinson's patients with medication-induced pathological
gambling: a [11C] FLB-457 and PET study. Neurobiol. Dis. 48, 519–525. https://doi.
org/10.1016/j.nbd.2012.06.021.
Reijnders, J.S.A.M., Ehrt, U., Weber, W.E.J., Aarsland, D., Leentjens, A.F.G., 2008.
A systematic review of prevalence studies of depression in Parkinson's disease. Mov.
Disord. 23, 183–189. https://doi.org/10.1002/mds.21803.
Ridderinkhof, R.K.R., Forstmann, B.U., Wylie, S.A., Burle, B., van den
Wildenberg, W.P.M., 2011. Neurocognitive mechanisms of action control: resisting
the call of the Sirens. Wiley Interdiscip. Rev. Cogn. Sci. 2, 174–192. https://doi.org/
10.1002/wcs.99.
Rigoli, F., Rutledge, R.B., Chew, B., Ousdal, O.T., Dayan, P., Dolan, R.J., 2016. Dopamine
increases a value-independent gambling propensity. Neuropsychopharmacology 41,
2658–2667. https://doi.org/10.1038/npp.2016.68.
Robbins, T.W., 2000. Chemical neuromodulation of frontal-executive functions in
humans and other animals. Exp. Brain Res. 133, 130–138. https://doi.org/10.1007/
s002210000407.
Robbins, T.W., Cools, R., 2014. Cognitive deﬁcits in Parkinson's disease: a cognitive
neuroscience perspective. Mov. Disord. 29, 597–607. https://doi.org/10.1002/mds.
25853.
Robbins, T.W., Rowe, J.B., Barker, R.A., 2016. Genetic neuroimaging studies of basal
ganglia disorders. In: Neuroimaging Genetics: Principles and Practices. Oxford
University Press, Oxford, New York, p. 416no.
Rothwell, J.C., Obeso, J.A., 2015. Can levodopa-induced dyskinesias go beyond the motor
circuit? Brain 138, 242–244. https://doi.org/10.1093/brain/awu365.
Rowe, J.B., Siebner, H.R., 2012. The motor system and its disorders. NeuroImage,
Neuroimaging: Then, Now and the Future 61, 464–477. https://doi.org/10.1016/j.
neuroimage.2011.12.042.92Rowe, J.B., Hughes, L., Ghosh, B.C.P., Eckstein, D., Williams-Gray, C.H., Fallon, S.,
Barker, R.A., Owen, A.M., 2008. Parkinson's disease and dopaminergic
therapy—differential effects on movement, reward and cognition. Brain 131,
2094–2105. https://doi.org/10.1093/brain/awn112.
Rowe, J.B., Hughes, L., Williams-Gray, C.H., Bishop, S., Fallon, S., Barker, R.A.,
Owen, A.M., 2010. The val158met COMT polymorphism's effect on atrophy in
healthy aging and Parkinson's disease. Neurobiol. Aging 31, 1064–1068. https://doi.
org/10.1016/j.neurobiolaging.2008.07.009.
Rutledge, R.B., Lazzaro, S.C., Lau, B., Myers, C.E., Gluck, M.A., Glimcher, P.W., 2009.
Dopaminergic drugs modulate learning rates and perseveration in Parkinson9s
patients in a dynamic foraging task. J. Neurosci. 29, 15104–15114. https://doi.org/
10.1523/JNEUROSCI.3524-09.2009.
Schapira, A.H.V., Chaudhuri, K.R., Jenner, P., 2017. Non-motor features of Parkinson
disease. Nat. Rev. Neurosci. 18, 435–450. https://doi.org/10.1038/nrn.2017.62.
Schmidt, L., Braun, E.K., Wager, T.D., Shohamy, D., 2014. Mind matters: placebo
enhances reward learning in Parkinson's disease. Nat. Neurosci. 17, 1793–1797.
https://doi.org/10.1038/nn.3842.
Schreiber, L.R.N., Odlaug, B.L., Grant, J.E., 2011. Impulse control disorders: updated
review of clinical characteristics and pharmacological management. Front. Psychiatr.
2. https://doi.org/10.3389/fpsyt.2011.00001.
Schultz, W., 2015. Neuronal reward and decision signals: from theories to data. Physiol.
Rev. 95, 853–951. https://doi.org/10.1152/physrev.00023.2014.
Schultz, W., 2017. Reward prediction error. Curr. Biol. 27, R369–R371. https://doi.org/
10.1016/j.cub.2017.02.064.
Shiner, T., Seymour, B., Wunderlich, K., Hill, C., Bhatia, K.P., Dayan, P., Dolan, R.J., 2012.
Dopamine and performance in a reinforcement learning task: evidence from
Parkinson's disease. Brain 135, 1871–1883. https://doi.org/10.1093/brain/aws083.
Skvortsova, V., Degos, B., Welter, M.-L., Vidailhet, M., Pessiglione, M., 2017. A selective
role for dopamine in learning to maximize reward but not to minimize effort:
evidence from patients with Parkinson9s disease. J. Neurosci. 37, 6087–6097.
https://doi.org/10.1523/JNEUROSCI.2081-16.2017.
Smith, K.M., Xie, S.X., Weintraub, D., 2016. Incident impulse control disorder symptoms
and dopamine transporter imaging in Parkinson disease. J. Neurol. Neurosurg.
Psychiatry 87, 864–870. https://doi.org/10.1136/jnnp-2015-311827.
Smittenaar, P., Chase, H.W., Aarts, E., Nusselein, B., Bloem, B.R., Cools, R., 2012.
Decomposing effects of dopaminergic medication in Parkinson's disease on
probabilistic action selection - learning or performance? Eur. J. Neurosci. 35,
1144–1151. https://doi.org/10.1111/j.1460-9568.2012.08043.x.
Spetsieris, P.G., Ko, J.H., Tang, C.C., Nazem, A., Sako, W., Peng, S., Ma, Y., Dhawan, V.,
Eidelberg, D., 2015. Metabolic resting-state brain networks in health and disease.
Proc. Natl. Acad. Sci. Unit. States Am. 112, 2563–2568. https://doi.org/10.1073/
pnas.1411011112.
Spraker, M.B., Prodoehl, J., Corcos, D.M., Comella, C.L., Vaillancourt, D.E., 2010. Basal
ganglia hypoactivity during grip force in drug naïve Parkinson's disease. Hum. Brain
Mapp. 31, 1928–1941. https://doi.org/10.1002/hbm.20987.
Steeves, T.D.L., Miyasaki, J., Zurowski, M., Lang, A.E., Pellecchia, G., Eimeren, T.V.,
Rusjan, P., Houle, S., Strafella, A.P., 2009. Increased striatal dopamine release in
Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.
Brain 132, 1376–1385. https://doi.org/10.1093/brain/awp054.
Stevenson, J.K.R., Talebifard, P., Ty, E., Oishi, M.M.K., McKeown, M.J., 2011. Dyskinetic
Parkinson's disease patients demonstrate motor abnormalities off medication. Exp.
Brain Res. 214, 471–479. https://doi.org/10.1007/s00221-011-2845-2.
Stevenson, J., Lee, C., Lee, B.S., Talebifard, P., Ty, E.B., Aseeva, K., Oishi, M.,
McKeown, M., 2014. Excessive sensitivity to uncertain visual input in L-DOPA-
induced dyskinesias in Parkinson's disease: further implications for cerebellar
involvement. Front. Neurol. 5. https://doi.org/10.3389/fneur.2014.00008.
Tahmasian, M., Bettray, L.M., van Eimeren, T., Drzezga, A., Timmermann, L.,
Eickhoff, C.R., Eickhoff, S.B., Eggers, C., 2015. A systematic review on the
applications of resting-state fMRI in Parkinson's disease: does dopamine replacement
therapy play a role? Cortex 73, 80–105. https://doi.org/10.1016/j.cortex.2015.08.
005.
Tang, C.C., Poston, K.L., Dhawan, V., Eidelberg, D., 2010. Abnormalities in metabolic
network activity precede the onset of motor symptoms in Parkinson's disease.
J. Neurosci. 30, 1049–1056. https://doi.org/10.1523/JNEUROSCI.4188-09.2010.
Timmer, M.H.M., Sescousse, G., van der Schaaf, M.E., Esselink, R.A.J., Cools, R., 2017.
Reward learning deﬁcits in Parkinson's disease depend on depression. Psychol. Med.
1–10. https://doi.org/10.1017/S0033291717000769.
Troiano, A.R., de la Fuente-Fernandez, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T.J.,
Stoessl, A.J., 2009. PET demonstrates reduced dopamine transporter expression in PD
with dyskinesias. Neurology 72, 1211–1216. https://doi.org/10.1212/01.wnl.
0000338631.73211.56.
Turner, R.S., Grafton, S.T., McIntosh, A.R., DeLong, M.R., Hoffman, J.M., 2003. The
functional anatomy of parkinsonian bradykinesia. NeuroImage 19, 163–179. https://
doi.org/10.1016/S1053-8119(03)00059-4.
van Eimeren, T., Ballanger, B., Pellecchia, G., Miyasaki, J.M., Lang, A.E., Strafella, A.P.,
2009. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a
trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology
34, 2758–2766. https://doi.org/10.1038/npp.2009.124.
van der Vegt, J.P.M., Hulme, O.J., Zittel, S., Madsen, K.H., Weiss, M.M., Buhmann, C.,
Bloem, B.R., Münchau, A., Siebner, H.R., 2013. Attenuated neural response to gamble
outcomes in drug-naive patients with Parkinson's disease. Brain 136, 1192–1203.
https://doi.org/10.1093/brain/awt027.
Vingerhoets, F.J.G., Schulzer, M., Calne, D.B., Snow, B.J., 1997. Which clinical sign of
Parkinson's disease best reﬂects the nigrostriatal lesion? Ann. Neurol. 41, 58–64.
https://doi.org/10.1002/ana.410410111.
D. Meder et al. NeuroImage 190 (2019) 79–93Vo, A., Sako, W., Fujita, K., Peng, S., Mattis, P.J., Skidmore, F.M., Ma, Y., Ulug, A.M.,
Eidelberg, D., 2017. Parkinson's disease-related network topographies characterized
with resting state functional MRI. Hum. Brain Mapp. 38, 617–630. https://doi.org/
10.1002/hbm.23260.
Voon, V., Pessiglione, M., Brezing, C., Gallea, C., Fernandez, H.H., Dolan, R.J., Hallett, M.,
2010. Mechanisms underlying dopamine-mediated reward bias in compulsive
behaviors. Neuron 65, 135–142. https://doi.org/10.1016/j.neuron.2009.12.027.
Voon, V., Gao, J., Brezing, C., Symmonds, M., Ekanayake, V., Fernandez, H., Dolan, R.J.,
Hallett, M., 2011. Dopamine agonists and risk: impulse control disorders in
Parkinson's; disease. Brain 134, 1438–1446. https://doi.org/10.1093/brain/awr080.
Voon, V., Rizos, A., Chakravartty, R., Mulholland, N., Robinson, S., Howell, N.A.,
Harrison, N., Vivian, G., Chaudhuri, K.R., 2014. Impulse control disorders in
Parkinson's disease: decreased striatal dopamine transporter levels. J. Neurol.
Neurosurg. Psychiatry 85, 148–152. https://doi.org/10.1136/jnnp-2013-305395.
Voon, V., Napier, T.C., Frank, M.J., Sgambato-Faure, V., Grace, A.A., Rodriguez-Oroz, M.,
Obeso, J., Bezard, E., Fernagut, P.-O., 2017. Impulse control disorders and levodopa-
induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. 16, 238–250.
https://doi.org/10.1016/S1474-4422(17)30004-2.
Vriend, C., Nordbeck, A.H., Booij, J., van der Werf, Y.D., Pattij, T., Voorn, P.,
Raijmakers, P., Foncke, E.M.J., van de Giessen, E., Berendse, H.W., van den
Heuvel, O.A., 2014. Reduced dopamine transporter binding predates impulse control
disorders in Parkinson's disease. Mov. Disord. 29, 904–911. https://doi.org/10.1002/
mds.25886.
Walton, M.E., Kennerley, S.W., Bannerman, D.M., Phillips, P.E.M., Rushworth, M.F.S.,
2006. Weighing up the beneﬁts of work: behavioral and neural analyses of effort-93related decision making. Neural Netw., Neurobiology of Decision Making 19,
1302–1314. https://doi.org/10.1016/j.neunet.2006.03.005.
Weintraub, D., Koester, J., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V.,
Whetteckey, J., Wunderlich, G.R., Lang, A.E., 2010. Impulse control disorders in
Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67,
589–595. https://doi.org/10.1001/archneurol.2010.65.
Wenzelburger, R., Zhang, B.-R., Pohle, S., Klebe, S., Lorenz, D., Herzog, J., Wilms, H.,
Deuschl, G., Krack, P., 2002. Force overﬂow and levodopa-induced dyskinesias in
Parkinson's disease. Brain 125, 871–879. https://doi.org/10.1093/brain/awf084.
Ye, Z., Altena, E., Nombela, C., Housden, C.R., Maxwell, H., Rittman, T., Huddleston, C.,
Rae, C.L., Regenthal, R., Sahakian, B.J., Barker, R.A., Robbins, T.W., Rowe, J.B.,
2015. Improving response inhibition in Parkinson's disease with atomoxetine. Biol.
Psychiatry 77, 740–748. https://doi.org/10.1016/j.biopsych.2014.01.024.
Ye, Z., Rae, C.L., Nombela, C., Ham, T., Rittman, T., Jones, P.S., Rodríguez, P.V., Coyle-
Gilchrist, I., Regenthal, R., Altena, E., Housden, C.R., Maxwell, H., Sahakian, B.J.,
Barker, R.A., Robbins, T.W., Rowe, J.B., 2016. Predicting beneﬁcial effects of
atomoxetine and citalopram on response inhibition in Parkinson's disease with
clinical and neuroimaging measures. Hum. Brain Mapp. 37, 1026–1037. https://doi.
org/10.1002/hbm.23087.
Zhuang, X., Walsh, R.R., Sreenivasan, K., Yang, Z., Mishra, V., Cordes, D., 2018.
Incorporating spatial constraint in co-activation pattern analysis to explore the
dynamics of resting-state networks: an application to Parkinson's disease.
NeuroImage 172, 64–84. https://doi.org/10.1016/j.neuroimage.2018.01.019.
